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“Look to this day, for yesterday is already a dream and tomorrow is only a vision.  
But today well lived makes every yesterday a dream of happiness, and every tomorrow a 
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I SUMMARY 
 
Human papillomaviruses (HPV) are the known cause for cancers of the cervix and are 
associated with a variety of other human malignancies including head and neck, and 
skin. The cottontail-rabbit papillomavirus (CRPV) serves as a suitable animal model to 
study the development and progression of these cancers in-vivo. Our group has 
previously demonstrated that CRPV-induced skin lesions express elevated levels of 
metalloproteinase-9, a protease contributing to cancer progression by extracellular 
matrix remodelling. Based on our previous findings that the CRPV early protein 2 (E2) 
can activate a truncated human MMP-9 promoter fragment, we hypothesized that 
enhanced MMP-9 expression in the rabbit lesions is a consequence of activation of the 
rabbit MMP-9 promoter by CRPV E2. In order to elucidate the mechanism involved in 
MMP-9 promoter activation a library of genomic DNA isolated from rabbit skin was 
constructed, and the sequence of the MMP-9 promoter was identified. Promoter deletion 
mutants were cloned and the minimum required fragment for E2-mediated MMP-9 
promoter activation was determined to be -717 bp in length. Selective mutation of 
transcription factor binding sites within the promoter sequence revealed a high 
importance of both of the two identified AP-1 binding sites in the rabbit MMP-9 promoter. 
Using the transactivation-deficient c-Jun mutant TAM67, a strong inhibitory effect on 
promoter activation after challenge with E2 could be observed, suggesting an important 
role of c-Jun in the activating AP-1 transcription-factor complex. The same mechanism 
could be shown in the human system during this study. Furthermore, it could be 
determined that in both, the rabbit and the human system, the activation of the MMP-9 
promoter by E2 requires the phosphorylation of the MAP-kinase ERK, as inhibition of the 
cascade by the chemical inhibitor PD098059 resulted in a significant decrease of 
promoter activation. Co-transfection of E2 and siRNA directed against ERK or a 
dominant-negative mutant of the latter led to similar results.  
It has been described previously that the high-risk HPV E2 is located within both nucleus 
and cytoplasm. Mutations in the domains responsible for protein localization allowed for 
investigation of the role of E2 localization in the activation of the MMP-9 promoter. It was 
observed that MMP-9 activation was strikingly decreased when the protein was mainly 
cytoplasmic. Additionally, HPV6bE2 which has been described to be solely nuclear did 
also induce MMP-9 promoter activation.  
It can hence be concluded that CRPV E2 and HPV16 E2 both activate the respective MMP-
9 promoters via an AP-1 and ERK dependent mechanism. As direct binding of the E2 
proteins to the promoter can be roled out, this mechanism has to be further investigated. 
It can, however, be hypothezised that the interaction of E2 with its potential interation 
partner is taking place within the nucleus.  
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II ZUSAMMENFASSUNG 
 
 
Infektionen mit humanen Papillomviren sind ursächlich für die Entstehung des 
Zervixkarzinoms und werden mit weiteren malignen Tumorerkrankungen des Menschen 
in Verbindung gebracht. Das einzige verfügbare Tiermodell zum Studium der 
Papillomavirus-assoziierten Tumorentstehung ist das Cottontail rabbit Papillomvirus 
(CRPV) Modell. Nach subkutaner Applikation der viralen DNA in Kaninchen kommt es zur 
Ausbildung von Papillomen, welche sich ohne Kofaktoren zu infiltrierenden Tumoren 
entwickeln. In vorausgehenden Studien unserer Gruppe konnte gezeigt werden, dass die  
CRPV-induzierten Hautläsionen des Kaninchens eine erhöhte Expression der 
Matrixmetalloproteinase-9 (MMP-9) aufwiesen. Dieser Protease wird eine wichtige Rolle in 
der Tumorigenese zugeschrieben, da sie an der Umstrukturierung und dem Abbau der 
extrazellulären Matrix beteiligt ist. Aufgrund der früheren Studien bei denen gezeigt 
wurde, dass das E2 Protein von CRPV in der Lage ist, eine verkürzte Form des humanen 
MMP-9 Promotors zu aktivieren, entstand die Vermutung, dass die gesteigerte Expression 
von MMP-9 in den CRPV-induzierten Hautläsionen eine Folge der Aktivierung des 
Kaninchen-MMP-9 Promotors ist. Um den zugrundeliegenden Mechanismus zu 
untersuchen, wurde zunächst eine DNA-Bibliothek mit genomischer DNA aus 
Kaninchenhaut erstellt und die Sequenz des Kaninchen-MMP-9 Promoters ermittelt. 
Promoter-Deletionsmutanten wurden kloniert und wir konnten nachweisen, dass 717 bp 
des Promoters ausreichend für die E2 induzierte Aktivierung sind. Selektive Mutationen 
von Transkriptionsfaktor-Bindestellen ergaben, dass beide im Kanichenpromoter 
identifizierten AP-1 Bindestellen von grosser Bedeutung für die Aktivierung sind. Auch 
Kotransfektion der transaktivierungsdefizienten c-Jun Mutante TAM67 zeigte eine 
deutliche Hemmung der E2 gesteuerten Promotoraktivierung, was auf eine bedeutende 
Rolle dieses fakultativen Bestandteils des AP-1 Komplexes hindeutet. Dieser 
Mechanismus konnte in dieser Arbeit auch im humanen System unter Zuhilfename des 
humanen Papillomavirus 16 (HPV16) aufgezeigt werden. Des Weiteren konnte die 
Abhängigkeit der Induktion des MMP-9 Promotors von einer Aktivierung der MAP-Kinase 
ERK sowohl im Kaninchen als auch im humanen System demonstriert werden. Die 
Inhibition der ERK-Kaskade durch den niedermolekularen Inhibitor PD098059, wie auch 
durch Kotransfektion von ERK siRNA oder dominant-negativen ERK Mutanten, mündete in 
einem Rückgang der E2-vermittelten Promotoraktivität. 
Es wurde zuvor beschrieben, dass das E2 Protein von Hochrisiko HPV-Typen im Nukleus 
sowie im Zytoplasma der infizierten Zelle zu finden ist. Mutationen in den Domänen des 
E2, die für die Proteinlokalisation verantwortlich sind, boten die Möglichkeit, die Rolle der 
Lokalisation von E2 in der Aktivierung des MMP-9 Promotors zu klären. Mutiertes E2, 
welches überwiegend im Zytoplasma der Zellen nachweisbar war, zeigte ein wesentlich 
geringeres Potential zur MMP-9 Promoteraktivierung. Zudem konnte gezeigt werden, 
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dass HPV6b E2, welches ausschliesslich nukleär vorliegt, ebenfalls in der Lage ist den 
MMP-9 Promotor zu aktivieren.  
Die hier vorliegenden Ergebnisse lassen die Schlussfolgerung zu, dass sowohl CRPV E2 
als auch HPV16 E2 die respektiven MMP-9 Promotoren über einen AP-1 und ERK-
abhängigen Mechanismus aktivieren. Da ausgeschlossen werden kann, dass die Proteine 
direkt den jeweiligen Promotor binden, bedarf der genaue Mechanismus weiterer 
Aufklärung. Es kann jedoch postuliert werden, dass eine Wechselwirkung von E2 mit 
einem potentiellen Interaktionspartner im Nukleus stattfindet.  
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III  ABBREVIATIONS 
 
AP-1   activator protein-1 
APS   ammonium persulfate 
ATF   activating transcription factor 
BCA   bicinchinonic acid 
BMK   big MAP-kinase 
BPV   bovine papillomavirus 
BS   binding site 
BSA   bovine serum albumine 
Cdk   cyclin-dependent kinase 
CR   conserved region 
CRPV   cottontail rabbit papillomavirus  
DAG   diaglycerin 
DBD   DNA-binding domain 
DMSO  dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
dNTPs  desoxyribonucleosid triphosphate 
ds    doublestranded 
EGF   epidermal growth factor 
E    early 
EBV   Epstein-Barr virus 
ECM   extracellular matrix 
ERK   extracellular signal-regulated kinase 
FAK   focal adhesion kinase 
H2Obidest  doubledestilled water 
HDAC  histone deacetylase 
HEPES  N-(2-hydroxethyl)piperazin-N'-(2-ethansulfonic acid) 
HNSCC  head and neck squamous cell carcinoma 
HPV   human papillomavirus 
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IGF   insulin-like growth factor 
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JNK   c-Jun N-terminal kinase 
L    late 
LCR   long control region 
LMP   late-membrane protein 
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MAPKK  mitogen-activated protein kinase kinase 
MAPKKK mitogen-activated protein kinase kinase kinase 
mRNA  messenger RNA 
MMP   matrix-metalloproteinase 
NES   nuclear export sequence 
NLS   nuclear localization sequence  
OD   optical density 
ORF   open reading frame 
PAA   polyacrylamide 
PAGE   polyacrylamide gel electrophoresis 
PAI   plasminogen activator inhibitor 
PBS   phosphate buffered saline 
PKC   protein kinase C 
PMA   see TPA 
RNA   ribonucleic acid 
RTK   receptor tyrosine kinase 
SAPK   stress-activated protein kinase 
SDS   sodium dodecylsulfate 
STAT   signal transducers and activators of transcription 
TBP   TATA-box binding protein 
TBS   tris buffered saline 
TEMED  tetramethyldiamine 
TGF   transforming growth factor 
TIMP   tissue-inhibitor of metallomproteinases 
tPA   tissue-type plasminogen activator 
TPA   12-otetradecanoylphorbol-13-acetate 
TRE   TPA-response element 
Tris   tris-(hydroxymethyl)methylglycine 
uPA   urokinase-plasminogen activator 
uPAR   uPA receptor 
URR   upstream regulatory region 
wt    wildtype 
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1 INTRODUCTION 
 
 
1.1 HUMAN PAPILLOMAVIRUSES 
 
Human papillomaviruses (HPVs) are small non-enveloped dsDNA viruses with a diameter 
of approximately 55 nm. The ikosaedric capsid that surrounds the viral DNA is composed 
of 72 capsomers (Klug and Finch, 1965) made up of the major capsid protein L1 and the 
minor capsid protein L2. The viral DNA is between 7.2 kb and 8 kb in length and 
maintained in a supercoiled closed circular episome associated with histone like particles 
(Favre et al., 1977; Pfister and zur Hausen, 1978). Depending on HPV type, up to 10 
open reading frames (ORFs) are occupying the transcriptionally active strand. The 
genome (Figure 1) can be devided into two coding regions which encode a variety of 
proteins which have been termed Early (E) or Late (L) proteins depending on the time of 
their expression in the infected cell (Ozbun and Meyers et al., 1997). While the early 
proteins have a mainly regulatory function, the late genes encode the capsid proteins. 
Gene expression is controlled by a long-control region (LCR), also termed upstream 
regulatory region (URR), which covers about 12% of the viral genome and contains 
several transcription-factor binding sites. 
 
 
 
 
 
 
 
Figure 1: Organization of the HPV16 genome. The genome is shown as a black circle with the early 
(p97) and late (p670) promoters marked by arrows. The six early ORFs E1, E2, E4 and E5 (green), E6 and 
E7 (red) are expressed from either p97 or p670 at different stages during epithelial cell differentiation. The 
late ORFs L1 and L2 (yellow). All the viral genes are encoded on one strand of the double-stranded circular 
DNA genome. The long control region (LCR) is enlarged to allow visualization of the E2-binding sites and the 
TATA element of the p97 promoter. The location of the E1- and SP1-binding sites is also shown. Modified  
from Doorbar, 2006. 
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1.1.1 The regulatory early proteins 1 and 2 
 
The E1 and E2 proteins are the major regulatory proteins and required for papillomavirus 
replication and transcription of the viral genes. They are highly conserved among 
different HPV types. 
 
The E1 protein is the largest of the HPV proteins with a size of about 70 kDa and is 
expressed throughout the HPV life cycle (Klumpp and Laimins, 1999). E1 is a DNA-
binding protein which posseses ATP-ase activtiy (Hughes et al., 1993). It also functions 
as an ATP-dependent DNA helicase (Hughes et al., 1993; Yang et al., 1993), unwinding 
double-stranded DNA molecules by utilizing energy obtained by the hydrolysis of ATP 
(Patel and Picha, 2000). The binding of E1 to viral DNA it rather week in the absence of 
E2, however, interaction with E2 enables efficient binding of E1 to the DNA (Mohr, 1990; 
Frattini and Laimins, 1994; Kuo et al., 1994; Sedman et al., 1997) where its monomers 
subsequently form a ring-shaped hexameric assembly which initiates the helicase activity 
(Sedman and Stenlund, 1998). E1 has further been shown to bind DNA polymerase alpha 
subunits and recruit those to the viral origin of replication (Masterson et al., 1998; 
Conger et al., 1999).  
 
The E2 protein contains approximately 360 amino acids and is 48 kDa in size. Is is 
composed of two domains which are seperated by a flexible hinge region (Giri and Yaniv, 
1988). The N-terminal part of the protein contains the transactivation domain while the 
C-terminus is occupied by the DNA-binding domain (DBD) (Sakai et al., 1996) and 
mediates the interaction of E2 with E1 (Sedman et al., 1997). Dimerized, the DBD 
recognizes E2-binding sites (E2BSs) consisting of the palindromic sequence 5΄-
AAC(N)6GTT-3΄ (McBride et al., 1991). The LCR of high-risk HPVs contains four highly 
conserved E2-binding sites suggesting that this specific arrangement is important for 
viral function (Stubenrauch et al., 1998). Two adjacent binding sites are located between 
binding sites for the cellular transcription factors Sp-1 and TBP (TATA-box binding 
protein), resulting in transcriptional repression (Dong et al., 1994; Romanczuk et al., 
1990; Thierry & Howley 1991) by steric inhibition of Sp-1 and TBP binding (Demeret et 
al., 1997; Dong et al., 1994; Stubenrauch et al., 1996; Tan et al., 1994). The remaining 
two E2BSs are positioned further upstream of the promoter and the binding of E2 to any 
of these sites mediates transcriptional activation (Romanczuk et al., 1990). E2 is 
suggested to be the major regulator of E6 and E7 expression. Loss of E2 expression can 
be detected in late stages of cervical cancer due to integration of the viral genome into 
the the host DNA and resulting disruption of the E2 ORF (Dürst et al., 1992; Klaes et al., 
1999). This may subsequently lead to increased cellular proliferation and further 
progression of carcinogenesis induced by E6 and E7 (Corden et al., 1999; Pett et al., 
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2004). Additionally, overexpression of HPV16 and -18 E2 proteins have been been shown 
to induce cell cycle arrest and apoptosis in cervical carcinoma cell lines (Desaintes et al., 
1997). As mutations eliminating the DNA-binding activity do not prevent E2-mediated 
apoptosis in HeLa cells (Webster et al., 2000) it has been suggested that the effect of E2 
on cell death is a result of its interaction with cellular proteins. Studies have led to the 
discovery that HPV16 E2 interacts with p53 (Massimi et al., 1999) and may induce 
apoptosis in a p53-dependent manner (Webster et al., 2000). As high-risk HPV E2 
proteins can be detected within both, the nucleus and the cytoplasm due to exportin-1 
receptor (CRM1)-dependent nucleo-cytoplasmic shuttling, while low-risk HPV E2 is strictly 
nuclear, these differences in localization may explain why high- but not low risk HPV E2 
has been shown to induce apoptosis in-vitro (Blachon et al., 2005). Furthermore, it has 
been recently shown that apoptosis can be induced by direct interaction of HPV18 E2 with 
caspase-8 (Thierry and Demeret, 2008). 
 
1.1.2 The early proteins E4 and E5  
 
The function of the E4 protein is largely unknown. It accumulates within the cell at the 
time of viral amplification, its mRNA being the major transcript found in HPV-induced 
lesions (Chow et al, 1987 a, b). The protein is not involved in transformation or the 
episomal maintenance of the viral DNA (Neary et al., 1987), but it is thought to play a 
role in late events of viral infection as these have been demonstrated to be disrupted 
upon loss of E4 in several experimental systems (Peh et al., 2004; Nakahara, et al., 
2005; Wilson et al., 2005). An association has been shown between E4 and the cells 
keratin cytoskeleton; an interaction that induces the collapse of the cytokeratin filament 
network, contributing to virus release from the cell (Doorbar et al., 1991; Roberts et al., 
1993). The protein also sequesters the Cdk1/cyclin B1 complex to the cytoskeleton, 
preventing it from accumulating within the nucleus and thus inducing G2 arrest 
(Nakahara et al., 2002; Raj et al., 2004) and a prolonged S-phase, promoting HPV 
genome amplification (Knight et al., 2004; Davy et al., 2005; Wilson et al., 2005).  
 
The E5 protein has appoximately 80 amino acids, and is a commonly dimeric hydrophobic 
membrane protein found predominantly in the membranes of the golgi, the endoplasmic 
reticulum, and the plasma membrane (Bubb et al., 1988; Halbert and Galloway, 1988; 
Burkhard et al., 1989; Conrad et al., 1993). While E5 was found to be the major 
transforming protein in bovine papillomaviruses (BPV) (Schiller et al., 1986; DiMaio et 
al., 1986; Rabson et al., 1986) where it forms a stable complex with the platelet-derived 
growth factor β receptor, inducing receptor dimerization and activation (DiMaio et al., 
2001), it is only weakly transforming in HPV (Leptak et al., 1991; Leechanachai et al., 
1992; Pim et al., 1992). In HPV16 transfected cells, E5 forms complexes with the 
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epidermal growth factor (EGF) receptors (Hwang et al., 1995) which impacts downstream 
signalling (Straight et al., 1993; Crusius et al., 1997, 1998; Zhang et al., 2002) and 
enhances mitogen-activated protein kinase (MAPK) activity (Gu et al., 1995). HPV16 E5 
also interacts with the vacuolar ATPase which results in the inhibition of acidification of 
the endosome (Conrad et al., 1993) and thus in inhibited degradation of internalized 
growth factor receptors ultimatly leading to increased recycling of the receptors to the 
cell surface (Straight et al., 1993, 1995). It also interferes with cell-mediated immune 
functions as it downregulates MHC class I molecules (Cartin and Alonso, 2003; Ashrafi et 
al., 2005) and perturbs MHC class II antigen maturation (Zhang et al., 2003) to repress 
host immune responses. 
 
1.2.3 The oncogenes E6 and E7 
 
The HPV16 E6 protein is relatively small with 151 amino acids and 18kDa. It contains 
four C-x-x-C motifs which probably lead to the formation of two zinc-fingers (Barbosa et 
al., 1989; Grossman et al., 1989; Kanda et al., 1991). However, the protein itself has no 
intrinsic enzymatic activity. E6 is located within both, cytoplasm and nucleus of the 
infected cell (Barbosa et al., 1989). It has been shown to exert transforming functions in 
various human cell lines, which seems to be caused by the interaction with cellular 
proteins (Band et al., 1990; Wazer et al., 1995; Reznikoff et al., 1996; Liu et al., 1999). 
The best studied function of the E6 protein is binding of the tumor supressor gene p53 
and the subsequent ubiquitin-mediated degradation of the latter. P53 has been shown to 
regulate the expression of genes involved in cell cycle control in response to a number of 
stimuli, including ionizing radiation, cell stress, or viral infection, upon which it mediates 
either cell cycle arrest or apoptosis (Werness, et al., 1990; Scheffner et al., 1990; Ko et 
al, 1996). Expression of high-risk E6 results in the formation of a trimeric complex with 
the cellular ubiquitin-ligase E6-AP, a complex which then leads to the ubiquitination of 
p53, resulting in reduced steady-state levels of p53 (Figure 2) (Huibregdse et al., 1991, 
1993; Kao et al., 2000). E6 can further downregulate p53-mediated transcription through 
the binding of CPB /p300, which are known co-activators of p53 (Lechner et al., 1994; 
Patel et al., 1999; Zimmermann et al., 1999). Another important function of high-risk E6 
is the activation of the catalytic subunit of human telomerase (hTERT) leading to an 
increase in telomeric length (Klingelhutz et al., 1996; Stoppler et al., 1997; Veldman et 
al., 2001; Gewin and Galloway, 2001; Oh et al., 2001). Additionally, E6 can activate 
hTERT transcription by binding directly to the transcription factor myc and recruiting it to 
the hTERT promoter (Veldman et al., 2001). It has been suggested that the induction of 
chromosomal instability by E6, resulting from the loss of G1/S checkpoint control due to 
the degradation of p53, is an important aspect for the long-term progression of latently 
high-risk HPV infected cells (Kessis et al. 1996).  
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HPV16 E7 is composed of 98 amino acids and has a molecular weight of approximately 
21 kDa. The protein appears to be situated predominantly within the nucleus and was 
shown to be phosphorylated in-vivo (Smotkin and Wettstein, 1987; Firzlaff et al., 1989; 
Barbosa et al., 1990; Smith-McCune et al., 1999). The N-terminal region of the protein 
contains three highly conserved regions (CR), CR-1, CR-2, and CR-3 (Barbosa et al., 
1990; Dyson et al., 1992). The CR-1 domain comprises the amino terminus and a 
domain corresponding partially to the conserved region 1 of the adenovirus E1A protein, 
a protein driving cells into S-phase. The CR-2 domain corresponds to the conserved 
region 2 of the adenovirus E1A protein completely, as well as to an analogous region in 
the cell-transforming SV40 large T antigen (Phelps et al., 1989). It further contains an 
LXCXE motif essential for binding the retinoblastoma protein (Rb) (Chellappan et al., 
1992; Dyson et al., 1992). Both, the CR-1 and the CR-2 domains impact the 
immortalizing potential of E7. The CR-3 domain consists of two zinc-finger motifs 
important for dimerization as E7 is predominantly present in a dimeric state (McIntyre et 
al., 1993; Braspenning et al., 1998; Phelps et al., 1992). The C-terminal portion of the 
protein contains two C-x-x-C motifs which form an unconventional zinc-finger region 
showing similarity to those found within the E6 protein and suggesting for an 
evolutionary relationship between the two (Phelps et al., 1989). The most intensely 
studied function of the E7 protein is its effect on the cell cycle mediated by its interaction 
with the so-called pocket proteins Rb, p107, and p130 (Berezutkaya et al., 1997; Dyson 
et al., 1989; Classon and Dyson, 2001). These pocket proteins bind the E2F family of 
transcription factors. Even though binding of E7 and E2F occurs at separate sites within 
the pocket of the proteins, the binding of E7 brings about the release of E2F (Lee et al., 
Figure 2: Effect of the E6 protein on p53. Upon DNA damage activated p53 
induces either cell cycle arrest or apoptosis. E6 (green) binds to p53 (light blue) 
when complexed with E6AP (dark blue) and thereby targets p53 for apoptosis. 
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1998), resulting in the constitutive activation of E2F-dependent genes which hence lead 
to unchecked cell proliferation (Berezutkaya et al., 1997; Huang et al., 1993; Patrick et 
al., 1994; Nguyen et al., 2002). Furthermore, binding of E7 to Rb targets the protein for 
ubiquitin-mediated degradation, leading to a reduction in Rb protein levels (Figure 3) 
(Phelps et al., 1992; Boyer et al., 1996; McCaffrey et al., 1999; Gonzales et al., 2001). 
While many other interactions of E7 with cellular proteins have been described and are of 
importance, such as binding to cyclin A/cdk-2 complexes and p107, histone deacetylases 
(HDACs), and TBP (Tommassino et al., 1993; McIntyre et al., 1996; Massimi et al., 
1997; Phillips et al., 1997; Brehm et al., 1999; Longworth and Laimins, 2004), they will 
not be described in detail. 
 
 
 
 
 
 
 
However, it should be mentioned that E7 was found to bind to the transcription factor 
activating protein 1 (AP-1) (described in detail under 1.6) and its subunits c-Jun, JunB, 
JunD, and c-Fos, an interaction that may be important in tumorigenesis (Antinore et al., 
1996; Nead et al., 1998). 
 
1.1.3 The structural proteins L1 and L2 
 
The capsid proteins L1 (57 kDa) and L2 (75 kDa) are expressed in the late stages of the 
viral life cycle (Stoler et al., 2000). Both proteins are synthesized in the cytoplasm of 
highly differentiated suprabasal cells (Ozbun and Meyers, 1997) and then are relocalized 
to the nucleus in order to package the HPV genomes. However, L1 capsomers are 
Figure 3: Effect of HPV E7 on Rb. The transcription factor E2F (yellow) is 
bound to Rb and released at the transition into S-phase. Binding of E7 (blue) to 
Rb (light blue) releases E2F, resulting in continuous activation of E2F-regulated 
genes and deregulated cellular proliferation. Furthermore, the binding of E7 to Rb 
targets the latter for degradation. 
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translocated into the nucleus through the nuclear core complex (Nelson et al., 2002), in 
contrast to L2, which uses the means of two nuclear localization sequences (NLSs) (Day 
et al. 2004).  
For formation of the HPV virion, the L1 proteins form pentameric stuctures which are 
stabilized by disulfite bonds. Upon packaging of the HPV genome, 72 pentameres are 
formed which contain the major (L1) and minor (L2) capsid proteins at a ratio of about 
30:1. While the L1 capsomers have been shown to expose neutralizing epitopes towards 
the viral surface which show vary extensively between different genotypes (Figure 4) 
(Dillner et al., 1999), it was proposed that the incorporation of L2 protein into the 
capsomer contributes to efficient DNA-packaging (Stauffer et al., 1998), and enhances 
the infectivity of the virus (Roden et al., 2001). 
 
 
 
 
 
 
 
1.1.4 HPV Infection and Cancer  
 
Papillomaviruses are highly species- and tissue specific. Human papillomaviruses infect 
the squamous epithelial cells of the skin and mucous membranes and bring about the 
formation of hyperproliferative lesions (warts). The life cycle of the virus is tightly linked 
to the differentiation of human keratinocytes and initial infection requires the availability 
of a cell that is still proliferating (zur Hausen, 1996). Within the first stage of the viral life 
cycle, the virus infects basal epithelial cells and establishes its genome episomally, 
maintaining a low copy number of 50-100 genome copies per cell. As the infected cell 
differentiates, the productive stage in the viral life cycle is initiated, where the late genes 
are expressed and the copy number is enhanced (Dürst et al., 1985; Chow and Broker, 
Figure 4: L1 capsomer structure. Two L1 pentamers are shown, colored by sequence conservation 
among a set of 49 different HPV types (HPV Compendium 1997: http://hpv-web.lanl.gov). Highly variable 
positions are red, fully conserved positions are blue and positions of average variation are white. All the 
hypervariable regions lie on the outward-facing surface of the pentamer. The C-terminal arm has several 
exposed, hypervariable residues (red and indicated by arrows). Modified from Modis et al., 2002. 
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1994; McMurray, et al., 2001). At the end of this stage, the virus DNA is encapsidated in 
the viral capsomers and the viruses are released by the differentiated cell (Figure 5).  
 
 
 
 
 
 
Transmission of HPV often occurs through microlesions in the skin, where cells in the 
basal layer are exposed to the surface (Oriel et al., 1971). Anogenital HPV types are 
most commonly transmitted through sexual contacts and infection with those types can 
rarely be detected in young women prior to first intercourse (Fairley et al., 1992; 
Andersson-Ellström et al., 1994; Rylander et al., 1994). Additionally, close correlations 
between the number of sexual partners and HPV infection have been described (Critchlow 
et al., 1995). Furthermore, oral-genital and oral-anal contacts may lead to an infection of 
oral sites with anogenital HPV types (Kashima et al., 1992, Gillisson, 2004).  
Most HPV types cause only benign cutaneous warts that quickly regress and are 
considered to be low risk. However, some types of HPV have been associated with human 
cancers and have been designated high risk. The high-risk HPV types most frequently 
found in human cancers are HPV16 and HPV18. Cervical cancer is the best-documented 
human cancer caused by infection. Here, development of malignant tumors is strongly 
correlated with high-risk HPV infection as their DNA can be detected in up to 99.8% of all 
cervical cancers. With about 500,000 cases reported worldwide, and about 275,000 
cancer deaths, cervical cancer is the second most common cause of cancer deaths in 
women (Parkin et al., 2005). The most commonly found HPV type in cervical cancer is 
HPV16 (up to 63%), followed by HPV18 (10-14%), HPV45 (~8%), and HPV31 (~5%) 
(Bosch et al., 2002; Clifford et al., 2003; Munoz et al., 2003).   
In addition to cervical cancer, HPV infection has also been described to play a role in 
several other malignancies such as of the penis, vulva, vagina, anus, head and neck, and 
skin (zur Hausen, 1996).  
Figure 5: The viral life cycle in differentiating epithelium. The key events that occur following 
infection are shown diagrammatically on the left. The different cell layers present in the epithelium are 
indicated on the left. The timing and extent of expression of the viral proteins are summarized using arrows 
at the right of the Figure and indicated by coloring of nuclei or whole cells. Modified from Doorbar, 2006.  
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HPV infections of the head and neck region can be accounted for by oral-genital and oral-
anal transmission as described above (Kreimer et al., 2004). HPV DNA can be detected in 
up to 25% of all squamous cell carcinomas of the head and neck region (HNSCCs) 
(Gillison, 2004) with the highest incidence in tumors of the oropharynx (~35%), followed 
by the oral cavity (~25%), and the larynx (~25%) with the most common HPV type 
being HPV16 (Chen et al., 2005). There are molecular, pathological, and prognostic 
differences between HPV-positive and –negative oropharyngeal cancers that include the 
presence of wt-p53 (Balz et al., 2003), higher sensitivity to radiation therapy (Mellin et 
al., 2000, Lindel et al., 2001; Strome et al., 2002), and significantly better prognosis for 
HPV-positive HNSCCs (Gillison 2000).  
 
1.2 THE COTTONTAIL RABBIT PAPILLOMAVIRUS (CRPV) 
 
The cottontail rabbit papillomavirus (CRPV), also known as Shope Papillomavirus was the 
first animal papillomavirus to be discovered (Shope and Hurst, 1933) and also the first 
mammalian DNA tumor virus. It was first described by Shope in 1933 to induce 
cutaneous papillomas (warts) in cottontail rabbits under natural conditions and in 
domestic rabbits under experimental conditions (Shope, 1935).  
In its natural host, CRPV causes a premissive infection where the systemic regression of 
warts can be detected in a variable proportion of rabbits as a consequence of a specific 
cell-mediated immune response (Evans and Ito, 1966; Kreider and Bartlett, 1981) 
resulting in clearance of the infection. Progression of persistent warts into invasive 
carcinomas as a result of an abortive infection can be observed in approximately 25% of 
cottontail rabbits. It was found that, when introduced into the skin of domestic rabbits, 
CRPV induces the formation of papillomas within approximately 8-12 weeks with about 
80% of these papillomas progressing into infiltrating and metastazising tumors within the 
course of a year without the need of co-factors (Shope, 1935). This makes it the 
“smallest” available animal model available to study the progression of benign papillomas 
to infiltrating carcinomas that mimics the development and progression of epithelial 
neoplasia associated with high-risk HPV. Furthermore, it allows for analysing the function 
of separate papillomavirus proteins and their mutants in-vivo. Hence it was found in a 
study by Jeckel et al. (2002) that mutations in a single amino acid in the transactivation 
domain of CRPV E2 within the context of the CRPV genome led to a drastic decrease of 
infection, causing only few papillomas none of which progressed into infiltrating 
carcinomas. One of the proteins shown to be increased in papillomas and carcinomas as 
compared to uninfected skin is the protease MMP-9 (Behren et al., 2005) which is known 
to play a role in tumor development and -progression. 
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1.3 TUMOR PROGRESSION 
 
The invasion of tumor cells into blood and lymph vessels and the establishment of 
metastases is often a critical stage in tumorigenesis for the patient. While the primary 
tumor is locally restricted and therefore accessible for treatment, the infiltration into 
surrounding tissues and organs drastically reduces survival rates.  
Tumor invasion itself is a multistage process which can be divided into three major parts, 
attachment, intravasation, and extravasation (Figure 6). These three steps, however, 
involve the detachment of malignant cells from the primary tumor, attachment of the 
cells to the structural barriers such as the basement membranes and surrounding 
stromal collagenous extracellular matrix (ECM), proteolysis of the barrier, intravasation 
of the tumor cells into blood and lymph vessels, circulation, attachment to the ECM at a 
distant site, and extravasation from the vessels to form a new tumor at the new site 
(Liotta et al., 1993; Stetler-Stevenson, et al., 1993). Upon reaching a certain size, the 
metastasis, as the primary tumor need to induce the formation of blood vessels, a 
process termed neovascularization, in order to carry nutrients to all parts of the tumor. 
Degradation of stromal ECM is also considered essential in tumor-induced angiogenesis 
(Stetler-Stevenson et al., 2001). 
 
 
 
 
 
 
 
Figure 6: Stages of tumor formation and progression. Initiation occurs when a single cell aquires a 
mutation which offers a growth adventage over the surrounding cells. At a certain size of the developing 
tumor requires neovascularization to supply the cell mass with nutrients. Some cells may detach from the 
cell mass, invade the surrounding tissue, and enter the blood or lymph vessels. At distant sites, the cells 
exit the circulation, and may be able to establish and form metastases. 
  INTRODUCTION  
   
  
 -11- 
The exact mechanisms required for tumor invasion are still to be uncovered, but it has 
been shown to involve the maintainance of a complex equilibrium of proteases, protease 
inhibitors and –activators, growth factors, pro-and anti-angiogenetic factors, and other 
biological effectors. 
 
1.4 PROTEASES 
 
The activity of proteases is required for the enzymatic degradation of matrices such as 
the extracellular matrix (ECM). Proteases known to play a role in this action include the 
members of the family of matrix metalloproteinases (MMPs) and the urokinase-
plasminogen activator system. The MMPs are able to degrade all components of the ECM, 
an activity required for physiological processes such as wound healing, angiogenesis, and 
invasion of immune cells into tissues, but also for pathological events as tumor 
development and –progression (McCawley and Matrisian, 2000). Binding of the serine-
protease urokinase-plasminogen activator (uPA) to its receptor (uPAR) leads to the 
conversion of plasminogen to plasmin which is able to cleave peptides such as laminin 
and fibronectin (Sidenius and Blasi, 2003). 
 
The family of matrix-metalloproteinases consists of more than 20 members which can be 
divided into several subgroups due to differences in structure and substrate specificity. 
These subgroups include collagenases, stromelysins, gelatinases, membrane-type MMPs, 
and others. The common structure of all MMPs includes a signal peptide, a propeptide, a 
catalytic domain with a highly conserved zinc-binding site, a hinge region, and a 
hemopexin-like domain (Figure 7). Most of the MMPs are secreted as inactive precursors 
(zymogens) that are proteolytically activated outside the cell by cleavage of the 
propeptide which exposes the catalytic site of the proteins (Figure 7) (Westermarck and 
Kähäri, 1999; Lee et al., 2004). MMPs are inhibited by the tissue inhibitors of 
metalloproteinases (TIMPs) which bind to the zinc-binding site at an equimolar ratio 
(Gomez et al., 1997).   
 
  INTRODUCTION  
   
  
 -12- 
 
 
 
 
One of the most important subgroups of MMPs is the group of the gelatinases. This group 
includes two members, MMP-2 (72kDa), which is expressed in a variety of normal and 
transformed cells, and MMP-9 (92kDa), which can be detected in keratinocytes, 
monocytes, and many types of malignant cells (Westermarck and Kähäri, 1999). 
Substrates of both enzymes include collagen V, a major component of the ECM, collagen 
I, vitronectin, fibronectin, and gelatin (Price et al., 1997). High MMP-2 expression was 
detected in gliomas, adenocarcinomas, and melanomas amongst others (Chintala et al., 
1999; Hofmann et al., 2000). Overexpression of MMP-9 was detected in many different 
epithelial cancers such as of the cervix (Davidson et al., 1999), head-and-neck, and skin 
(Juarez et al., 1993; Ikebe et al., 1999; Magary et al., 2000; Davidson et al., 1999; 
Jones et al., 1999). The overexpression of both gelatinases correlates with the lymph 
node status of patients with squamous-cell carcinomas of the head-and-neck. For 
decades, these protases have been investigated under the aspect of degradation of the 
ECM and the creation of a matrix defect. Only within the last couple of years the focus of 
researchers has shifted to events that play major roles in tumorigenesis besides 
infiltration.  
Figure 7: Matrix-metalloproteinases in tumor development and –progression. Illustration of the 
structure and key roles of MMPs in tumorigenesis.  
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It was found that MMP-9 and uPA play an important role in the migration of cells, the 
release and activation of growth factors, the supply of chemotactic substances, and have 
been shown to interact with a great number of biological effectors. MMP-9 can induce the 
motility of tumor cells through the degradation of cell-cell and cell-matrix molecules such 
as E-cadherin and CD44 and thereby promote the detachment of small cell clusters from 
the primary (Seiki, 2003; Noe et al., 2001). After proteolytical processing of matrix 
proteins such as laminin and fibronectin, cryptic sites that can induce chemotaxis and 
also participate in the regulation of MMP expression may be exposed (Brassart et al., 
2001; Björklund and Koivunen, 2005). Furthermore, growth factors that are localized 
within the ECM such as the insulin-like growth factor II (IGFII) or the transforming 
growth factor beta (TGF-beta) are released by the action of MMP-9 and may 
subsequently enhance tumor growth (Yu and Stamenkovic, 2000; Whitelock et al., 
1996). Despite these factors promoting tumor growth, the degradation of the ECM also 
leads to the formation of pro-angiogenic factors. Endostatin and restin, for example, are 
generated by the cleavage of Collagen XVIII or XV (Patterson and Sang, 1997; Marneros 
and Olsen, 2001; Ferreras et al., 2000).  
 
The urokinase plasminogen activator (uPA) system consists of the serine proteases uPA 
and tPA (tissue-type plasminogen activator), the endogenous plasminogen activator 
inhibitors (PAI-1 and -2), and the uPA receptor (uPAR) (Sidenius and Blasi, 2003). Many 
studies describe a correlation between uPA/uPAR expression and the diagnosis of cancer 
(Curino et al., 2004; Nielsen et al., 2005; Ohba et al., 2005). It has also been suggested 
that the uPA system is involved in multiple steps of tumor progression such as cell 
migration, adhesion, and signal transduction (Duffy, 2004). The latter can be the result 
of direct activation of growth factors such as the pro-hepatocyte growth factor (pro-HGF) 
(Naldini et al., 1995) or an indirect effect as observed after the conversion of 
plasminogen to plasmin by uPA and the subsequent activation of released cytokines 
(Sato et al., 1990; George et al., 2005). In some cells, the binding of uPA to uPAR results 
in the activation of signal-transduction cascades such as the extracellular-regulated 
kinase (ERK) or the signal transducers and activators of transcription (STAT) pathway (Jo 
et al., 2002), influencing the expression of other tumor-progression promoting genes.  
 
MMP-9 and uPA are often found to be co-expressed and the expression of both is mainly 
regulated by the mitogen-activated protein kinase (MAPK) pathway. 
 
1.5 THE MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) PATHWAYS 
 
The MAPKs are signal-transduction cascades which traffic signals from the outside of a 
cell to its nucleus via a number of phosphorylation events. Within the nucleus, the MAPKs 
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induce changes in the gene expression pattern as a response to the stimulus by direct or 
indirect modulation of several transcription factors (Robinson and Cobb, 1997). To date, 
five MAP-kinases have been identified, the extracellular-regulated kinases 1/2 (ERK1/2 or 
p42/p44), the c-jun N-terminal kinases 1, -2, and -3 (JNK), the p38 kinase with its 
isoforms p38-α, -β, -γ, and –δ, ERK3/4, and ERK5 (also known as Big Map-Kinase-1, 
BMK-1) (Chen et al., 2001). However, the most important members are the ERK-cascade 
as “classical” MAPK, and p38 and JNK, the stress-activated protein kinases (SAPK) 
(Figure 8).  
 
 
 
 
 
 
A broad spectrum of stimuli is involved in the activation of MAP-kinases, while it can be 
generalized that the ERK-cascade is stimulated by growth factors, protein kinase C 
(PKC), and tumor-inducing substances such as phorbol ester (PMA), which mimics 
Diaglycerin (DAG) derived from the IP3 pathway. JNK and p38 on the other hand are 
activated by stress factors such as UV-light, osmotical and mechanical stresses, and 
cytokines (Pearson et al., 2001). All three signal-transduction cascades are constructed 
similarly and consist of three kinases involved in passing the signal. The first 
phosphorylation step is mediated by an interaction between MAPK-kinase-kinases 
(MAPKKKs or MEKKs) with GTP-binding proteins of the Ras/Rho family. In this step, the 
MAPKKKs are phosphorylated at serin/threonine side-chains and subsequently 
phosphorylate MAPK-Kinases (MAPKKs or MEKs) which then dually phosphorylate the 
MAP-Kinases at tyrosin and threonine side-chains (Arbabi and Maier, 2002). Upon 
activation, the MAP-Kinases then relocate to the nucleus by yet to be determined 
Figure 8: The mitogen-activated protein kinases. Summarizing illustration of 
the MAPK pathways, their stimuli, and responses. Modified from Cell Signaling 
Technologies.  
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mechanisms. All three MAPK-pathways can interact in-vitro and in-vivo but one of the 
common features is their ability to influence the transcription factor complex AP-1 
through the activation of a diverse set of intranuclear targets (Pearson et al., 2001)). 
 
The ERK-cascade is the best characterized of the three MAP-Kinase pathways. It has 
been described to play a keyrole in cell proliferation and is activated mainly through the 
action of growth factors (Lewis et al., 1998). This activation usually occurs through 
autophosphorylation of ligand-bound receptor tyrosine kinases (RTKs), recruitment of the 
GTP/GDP conversion factor son of sevenless (SOS), activation of members of the Ras 
family of proteins and their interaction with effectors of the Raf proteins (Daum et al., 
1994; Kolch, 2000). Activated Raf can subsequently phosphorylate MEK1 and -2 which 
leads to the activation of ERK1 and -2.  
Ras and Raf isoforms are of special interest in the regulation of growth processes. 
Mutated Ras has been detected in about 30% of all human malignancies and mutations 
in Raf proteins have been described to be present in high percentages in certain kinds of 
tumors (Barbacid, 1987; Bos, 1989). Inhibition of the ERK-cascade has been shown to 
reduce invasion in transformed cell lines and primary tumors. It was further described 
that ERK1/-2 as well as JNKK participate in the regulation of in-vitro invasion of NIH3T3 
cells that have been stably transfected with oncogenic Ras (Janulis et al., 1999).  
However, besides its influence on cell proliferation and invasion the ERK-cascade has 
more recently also been connected to an increase in cell motility. By activating Calpain-2, 
a protease involved in the detachment and migration of cells and the eventual 
degradation of focal adhesion kinase (FAK) and other adhesion proteins, ERK governs the 
migration of cells (Bhatt et al., 2002; Carragher et al., 2003; Huttenlocher et al,. 1997). 
Apart from the above mentioned activators, several viral proteins such as the late 
membrane protein-1 (LMP-1) of the Epstein-Barr virus (EBV) and the E5 protein of HPV 
have also been shown to induce the ERK-cascade and hence influence cell proliferation 
and the expression of several genes which promote tumor progression (Roberts and 
Cooper, 1998; Crusius et al., 2000). 
 
To date, four p38 isoforms have been described; p38-α, -β, -µ, and –δ (Enslen et al., 
1998). Of these, p38-α and –β are expressed ubiquitously, whereas p38-µ, and –δ-
expression is tissue specific (Eckert et al., 2003). All four isoforms share a common 
amino acid motif (Thr-Gly-Tyr) at which they can become dually phosphorylated 
(Raingeaud et al., 1995). Inflammatory processes are closely connected to the p38-
pathway, while their role in tumorigenesis remains widely unknown. Studies point to an 
enhanced activation of p38 in infiltration events and propose a role for p38 in the 
regulation of different tumor-progression promoting proteases such as uPA, MMP-1, 
MMP-9, and MMP-13 (Bernstein and Colburn, 1989; Reunanen et al., 2002; Han et al., 
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2002). Active forms of p38 could also be detected in tumors of the lung, breast, and 
stomach (Greenberg et al., 2002; Salh et al., 2002). On the contrary, a close connection 
between an enhanced p38 activity with senescence and apoptosis is being discussed in 
other studies (Kummer et al., 1997; Holmes et al., 2003; Haq et al., 2002). The role of 
the p38-pathway therefore seems to be individually determined by the cell line, the 
stimulus, and potential interactions with other signalling proteins. 
 
The JNK-cascades belong to the SAPKs. They are activated by the same stimuli as the 
p38 cascade and are encoded by three different genes, JNK1, JNK2, and JNK3. While 
JNK1 and JNK2 are expressed ubiquitously, the expression of JNK3 is limited to certain 
tissues (Davis, 2000). Within the nucleus, the JNK proteins phosphorylate a set of 
transcription factors such as ATF-2 and c-jun, and thereby play part in the regulation of 
the transcription-factor complex AP-1. They also phosphorylate c-jun at residues Ser63 
and Ser73 within its N-terminal transactivation domain (Hibi et al., 1993). This stabilizes 
and activates c-Jun, which results in the enhanced transcriptional activation of c-Jun 
dependent genes (Musti et al., 1997). Furthermore, the activity of JNK seems to be 
connected to apoptosis as well as to the transformation of cells, as has been described 
for the p38-cascade (Pedram et al., 1998; Tournier et al., 2000). 
 
1.6 THE TRANSCRIPTION FACTOR AP-1 
 
The activator protein 1 (AP-1) transcription-factor complex is formed by different dimer 
compositions of members of the Jun (c-Jun, JunB, and JunD) and Fos (c-Fos, FosB, Fra-
1, and Fra-2) protein families, and some members of the activating transcription factor 
(ATF) (Bakiri et al., 2002), JDP, and musculoaponeurotic fibrosarcoma (MAF) subfamilies 
(Matsushima-Hibiya et al., 1998; Li et al., 1999). The Jun and Fos family members 
belong to the immediate early genes (IE) (Herschman et al., 1991). These IE genes are 
induced within short periods after the treatment of cells with a variety of physiological, 
pathological and oncogenic stimuli, like the epidermal growth factor EGF (Kajanne et al., 
2007), tumor necrosis factor TNF-a (Brenner et al., 1989), and 12-
otetradecanoylphorbol-13-acetate (TPA or PMA) (Espino et al., 2006). Hence, AP-1 is 
involved in the induction and regulation of cellular responses reaching from proliferation 
to apoptosis (Angel and Karin, 1991; van Dam and Castellazzi, 2001). Whereas members 
of the Jun protein family are able to form homo- (Grondin et al., 2007) as well as 
heterodimers (Turner et al., 1989), the Fos protein family members always 
heterodimerize (Smeal et al., 1989). Depending on stimulus, tissue type, and duration of 
induction, the proteins which form the AP-1 transcription factor vary (Hess et al., 2004). 
Furthermore, the composition of the dimer defines which genes are further induced 
(Chalmers et al., 2007). Fos and Jun proteins have first been described as the viral 
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oncoproteins v-Fos and v-Jun in the Finkel-Biskis-Jinkins osteosarcoma virus (Curran et 
al., 1982) and avian sarcoma virus 17 (Maki et al., 1987), respectively. All AP-1 proteins 
are characterized by an evolutionary conserved leucin zipper domain (bZIP) which is 
needed for the dimerisation and a basic domain which allows for the interaction with the 
DNA backbone (Turner et al., 1989; Smeal et al., 1989) after the dimer is formed. 
Several different DNA sequences are recognized by AP-1, the most affine of which is the 
TPA response element (TRE; consensus sequence 5’-TGAG/CTCA-3’), but different dimers 
also bind to the cAMPrespose element (CRE), the MAF recognition elements (MAREs) and 
the antioxidant response elements (AREs) (Sng et al., 2004; Hess et al., 2004).  
A couple of mechanism exist by which AP-1 activity is regulated including changes in 
transcription of subunit-encoding genes, control of the stability of mRNAs, and post-
translational processing (Hess et al., 2004). The most extensively studied mechanism of 
post-translational control is stress- or mitogen-induced hyperphosphorylation of c-Jun by 
MAPKs.  
 
AP-1 is required for the transcription of HPV (Offord and Beard, 1990; Kyo et al., 1997) 
in addition to several other cellular transcription factors that regulate HPV transcription 
from the HPV enhancer region (Chong et al., 1991). However, only few transcription-
factor binding sites have been found in all HPV types studied, as was the case for AP-1 
(del Mar Pena and Laimins, 2001). There may be more than one binding site for AP-1 in 
the LCR, such as 3 in HPV16 and 2 in HPV18. Mutagenesis of one binding site in HPV18 
leads to suppression of the HPV transcription (Butz and Hoppe-Seyler, 1993). In addition, 
similar to the regulation of cellular events, the composition of the AP-1 transcription 
factor complex is essential for HPV transcription (Soto et al., 1999). Previous studies 
have shown that the induction of changes in the AP-1 composition influences 
transcription of the HPV genome (Rösl et al., 1997) and therefore that AP-1 composition 
is pivotal for HPV transcription (Soto et al., 1999). Fusing HPV18 positive HeLa cells with 
normal fibroblasts yields two different kinds of hybrid cell lines, one of which is non-
tumorigenic in immunodeficient nude mice, whereas the other hybrid cell line and HeLa 
cells induce tumors under the same experimental settings (Soto et al., 1999). Treatment 
with TNF-α induces down-regulation of HPV expression within the non-malignant hybrid 
cells (Rösl et al., 1994) due to enhanced expression of Fra-1 and resulting changes in the 
AP-1 composition from predominantly Jun/Jun or Jun/Fos to Jun/Fra-1 heterodimers. This 
suppression of viral transcription is not detectable in HeLa cells or in tumorigenic hybrid 
cells after incubation with TNF-α. Furthermore, ectopical expression of c-fos in non-
tumorigenic cells resulted in a change in AP-1 composition towards Jun/Fos 
herterodimers over Jun/Fra-1 dimers and subsequent conversion into tumorigenic cells 
(Soto et al., 1999).  
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1.7 AIM OF THIS STUDY 
 
The action of Matrix-metalloproteinse 9 has been associated with tumor-initiation and –
progression. MMP-9 overexpression was shown in a variety of human cancers. In CRPV 
induced papillomas and carcinomas as compared to uninfected rabbit skin, an expression 
of MMP-9 has been observed. Further, it has been shown that CRP-viruses encoding 
transactivation-deficient E2 proteins are impaired in the induction of papillomas. 
  
The aim of this study was to clone and sequence the rabbit MMP-9 promoter and to 
investigate the mechanism by which the Papillomavirus early proteins, with emphasis on 
E2, induce activation of the MMP-9 promoter. This was meant to be schieved by meant of 
promoter deletion mutants and transcription-factor binding site mutants. Additionally, 
MAP-kinases involved in the activation of the promoter were to be investigated using 
chemical inhibitors of the respective MAPKs.  
All experiments carried out in the rabbit system were parallel to be carried out in the 
human system using HPV16 early proteins and the human MMP-9 promoter to enable the 
comparison of the two systems. 
 
Localization studies using HPV16 E2 were to be conducted in later stages of the study to 
obtain an insight whether the localiation of the proteins impacts the induction of MMP-9 
expression.  
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2 EXPERIMENTAL PROCEDURES 
 
2.1 MATERIALS 
 
2.1.1 Chemicals 
 
All chemicals used in this study were of analytical grade. They were purchased from Carl 
Roth (Karlsruhe, Germany), Invitrogen (Karlsruhe, Germany), Sigma (Munich, Germany), 
and Jena Biosciences (Jena, Germany) unless stated otherwise. 
 
2.1.2 Oligonucleotides  
 
Table 1: List of oligonucleotides. 
Name Sequence  
AP1 5'-GTAATACGACTCACTATAGGGC-3' 
AP2 5'-ACTATAGGGCACGCGTGGT-3' 
MMP9 Promoter for 5'- GCCTCAGAGACCCACTCCTTCCG-3' 
MMP9forwBegin 5'-AACCCAGTCGCCTATACCTG-3' 
MMP9forwSeq 5'-GCCGGCCGTGAGCCTGTCCTAC-3' 
MMP9forwSeq2 5'-GGGTGAGAAGTAGAGCTGGGGCTG-3' 
MMP9neu4 5'-CAGCCGGCCAGCCTTCTCTGACTCCAAG-3' 
MMP9PromreversSeq 5'-CCCGCAGGCTACGTCCTCCCTCCTGG-3' 
MMP9PromrevSeq2 5'-CGGAAGGAGTGGGCTCTCTAGG-3' 
MMP9PromSabfor 5'-GGGAGAGGAAGCTGAGTC-3' 
MMP9Sabrev 5'-AGGCAAGTGCTGACTCAG-3' 
NZWMMP9revnest2 5'-ATGGTGAGGGGAGCAGCGTCTGGC-3' 
MMP9ForKpn2 5'-AACCCATTCGCCGGTACCTGGTCCTCTC-3' 
MMP9RevKpn2 5'-GAGCGCCAGGTACCAGGGGCTG-3' 
MMP9PhumKpnF 5'-GCAGGTACCTACCCACTTCTATACCTGGG-3' (KpnI) 
MMP9PhumKpnR 5'-GGTACCAGAGGCTCATGGTGAGGG-3' (KpnI) 
rMP-1550 5'-GGAACTGGTACCAGAGCTGGGACG-3' (KpnI) 
rMP-1225 5'-GAACGGGGAGGTACCAGCTGAGG-3' (KpnI) 
rMP-953 5'-GGGGAGAGAATGCCAGGTACCTTGTAC-3' (KpnI) 
rMP-717 5'-GTCACAGCATGGTACCAACACCTGCC-3' (KpnI) 
rMP-493 5'-CCAGCTGGTACCGGGAGGAGG-3' (KpnI) 
rMP-144 5'-GTTCTTTGGTACCTTCTCATGCTGGGGC-3' (KpnI) 
rMPrev 5'-GAGCGCCAGGTACCAGGGG-3' (KpnI) 
MMP9Ende 5'-GCTCCCCTCACCATGAGCC-3' 
hMP-1785 5'-TAAGGTACCTGGCACATAGTAGGCC-3' (KpnI) 
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hMP-1261 5'-AATGGTACCATGGAGCAGGGC-3' (KpnI) 
hMP-829 5'-ATTGGTACCTCACATCAATTTAGGGACAAAG-3' (KpnI) 
hMP-670 5'-TCGGTACCCCTGAAGATTCAGC-3' (KpnI) 
hMPrev 5'-CTGCCAGAGGTACCCTCATG-3' (KpnI) 
rMP-AP1-distal-for 5'-CGCCCAGCTGGAGCCGGGAGGAGGAAGCGGAGTCAGGAG 
GAGGGC-3' 
rMP-AP1-distal-rev 5'-GCCCTCCTCCTGACTCCGCTTCCTCCTCCCGGCTCCAGC 
TGGGCG-3' 
rMP-AP1-proximal-for 5'-CCCCCCTGCACCGGCCCGGAGTCAGGCACTTGCCTGC-3' 
rMP-AP1-proximal-rev 5'-GCAGGCAAGTGCCTGACTCCGGGCCGGTGCAGGGGGG-3' 
rMP-MyoDmt-for 5'-CACTCTGCAAATACTTGCAACAGCCGCGTGCCGGGCCAA 
GAGC-3' 
rMP-MyoDmt-rev 5'-GCTCTTGGCCCGGCACGCGGCTGTTGCAAGTATTTGCAG 
AGTG-3' 
rMP-E47mt-for 5'-GCGTCTCCCACGAAGGTGGCAGGGACTCAAGTACTTGAG 
CCG-3' 
rMP-E47mt-rev 5'-CGGCTCAAGTACTTGAGTCCCTGCCACCTTCGTGGGAGA 
CGC-3' 
rMP-ETS1-for 5'-CCCAGGGTGACACCAGCATGAAGCTGGGTGAGAAGTAGA 
GC-3' 
rMP-ETS1-rev 5'-GCTCTACTTCTCACCCAGCTTCATGCTGGTGTCACCCTG 
GG-3' 
rMP-ETS2-for 5'-GGCTGGAACCCAGGCCCTCCAGTGCATGATGCAAGCATC 
C-3' 
rMP-ETS2-rev 5'-GGATGCTTGCATCATGCACTGGAGGGCCTGGGCTCCAGC 
C-3' 
hMP-E2mut-for 5'-GCAGCTTAGAGCCCAATAACATGGTTTTGTGATTCCAAG-3' 
hMP-E2mut-rev 5'-CTTGGAATCACAAAACCATGTTATTGGGCTCTAAGCTGC-3' 
hMP-AP1-distal-for 5'-GAAGCAGGGAGAGGAAGCTTTGTCAAAGAAGGCTGTCAG 
G-3' 
hMP-AP1-distal-rev 5'-CCTGACAGCCTTCTTTGACAAAGCTTCCTCTCCCTGCTT 
C-3' 
hMP-AP1-proximal-for 5'-CACACCCTGACCCCTTTGTCAGCACTTGCCTG-3' 
hMP-AP1-proximal-rev 5'-CAGGCAAGTGCTGACAAAGGGGTCAGGGTGTG-3' 
EEcoRIF 5'-TATGAATTCATCCTCCAAAATCGGATC-3' (EcoRI) 
EXhoR 5'-ATACTCGAGATCGTCAGTCAGTCA-3' (XhoI) 
eGFPtagF 5'-TAGAATTCTAATTGGTGAGCAA-3' (EcoRI) 
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16E2I73A 5'-GGCTGTATCAAAGAATAAAGCATTACAAGCAGCTGAACTGC 
AACTAACGT-3' 
16E2I73A-r 5'-ACGTTAGTTGCAGTTCAGCTGCTTGTAATGCTTTATTCTTTG 
TACAGCC-3' 
NLS1 (107/108) 5'-GTGTATTTAACTGCACCAAAACGATGTATAAAAAAACAT 
GGATATACAGTGGAAGTGC-3' 
NLS1 (107/108)rev 5'-GCACTTCCACTGTATATCCATGTTTTTTTATACATCGTTTTG 
GTGCAGTTAAATACAC-3' 
NLS2 (241/244) 5'-CACAGACGACTATCCAGCGAAAAAGATCACGGCCAGACAC 
CGGAAACCCC-3' 
NLS2 (241/244)rev 5'-GGGGTTTCCGGTGTCTGGCCGTGATCTTTTTCGCTGGATA 
GTCGTCTGTG-3' 
NESmt L-P 5'- GCATTACAAGCAATTGAACTGCAACCAACGTTAGAAACAA 
TATATAACTCAC-3' 
NESmt L-P rev 5'-GTGAGTTATATATTGTTTCTAACGTTGGTTGCAGTTCAATT 
GCTTGTAATGC-3' 
NESdel (del217-237) 5'-GCTGTATCAAAGAATAAAGCATTACAAGCA_GAAACAATA 
TATAACTCACAATATAGTAAT-3' 
NESdel (del217-237)rev 5'-ATTACTATATTGTGAGTTATATATTGTTTC_TGCTTGTAAT 
GCTTTATTCTTTGATACAGC-3' 
NLSDBDmt 5'-GATGCTAATACTTTAAAATGTTTAGGATATGGATTTACAAAG 
CATTGTACATTGTATACT-3' 
NLSDBDmt rev 5'-AGTATACAATGTACAATGCTTTGTAAATCCATATCCTAAACA 
TTTTAAAGTATTAGCATC-3' 
16E2 306/307 5'-ACTTTAAAATGTTTAAGATATAGATTTGCAGCGCATTGTACA 
TTGTATACTGCAGTGTC-3' 
16E2 306/307 rev 5'-GACACTGCAGTATACAATGTACAATGCGCTGCAAATCTATA 
TCTTAAACATTTTAAAGT-3' 
  
QPRCPlauHRev 5'-CCAGCTCACAATTCCAGTCA-3' 
QPRCPlauHFor 5'-GTCACCACCAAAATGCTGTG-3' 
QPCRJUNhFor 5'-TAACAGTGGGTGCCAACTCA-3' 
QPCRJUNhRev 5'-TTTTCTCTCCGTCGCAACTT-3' 
QPCRMMP9hFor 5'-CGACGTCTTCCAGTACCGA-3' 
QPCRMMP9hRev 5'-CTCAGGGCACTGCAGGAT-3' 
QPCRACTBhFor 5'-GCACAGAGCCTCGCCTT-3' 
QPCRACTBhRev 5'-CCTTGCACATGCCGGAG-3' 
QPCRGAPDHhFor 5'-CTCTGCTCCTCCTGTTCGAC-3' 
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Restriction sites are indicated in italics, restriction endonucleases are given in parentheses, nucleotide 
exchanges are marked in bold. 
 
 
2.1.3 siRNAs 
 
Table 2: List of siRNAs. 
Name Sequence (5'  3') 
siRNA MAPK3 sense r(CGU CUA AUA UAU AAA UAU A)dTdT 
siRNA MAPK3 antisense r(UAU AUU UAU AUA UUA GAC G)dGdG 
siRNA MAPK1 sense r(CAU GGU AGU CAC UAA CAU A)dTdT 
siRNA MAPK1 antisense r(UAU GUU AGU GAC UAC CAU G)dAdT 
siRNA Raf1 sense r(GAC GUU CCU GAA GCU UGC C)dTdT 
siRNA Raf1 antisense r(GGC AAG CUU CAG GAA CGU C)dTdT 
 
 
2.1.4 Plasmids 
 
Table 3: List of plasmids. 
Name  Characteristic trait Reference 
pCAT3 Basic chloramphenicol acetyltransferase 
gene (CAT) without promoter 
Promega, Mannheim, 
Germany 
pCATrMPFL full length rabbit MMP-9 promoter; 
CAT 
this study 
pCATrMP-1225 1225bp of the rabbit MMP-9 
promoter; CAT 
this study 
QPCRGAPDHhRev 5'-TTAAAAGCAGCCCTGGTGAC-3' 
qPCRHPV16E2 5'-ATGGAGGACTCTTTGCCACG-3' 
qPCRHPV16E2rev 5'-CCTGTTGGTGCAGTTAAATACAC-3' 
QPCRHPV16E6for 5'-ACTGCAATGTTTCAGGACCC-3' 
QPCRHPV16E6rev 5'-TCAGGACACAGTGGCTTTTG-3' 
QPCRHPV16E7for 5'-CCCAGCTGTAATCATGCATG-3' 
QPCRHPV16E7rev 5'-TGCCCATTAACAGGTCTTCC-3' 
rMMP9qPCRfor 5'-CTGGGCAAGGGCGTCGTGGTC-3' 
rMMP9qPCRrev 5'-CGTGGTGCAGGCGGTGTAGGAG-3' 
qPCRCRPVE2 5'-ATGGAGGCTCTCAGCCAGCGCTTAG-3' 
qPRCCREPE2rev 5'-CCTTTCTCTACTGGTATCCTGCAATGTCCATGG-3' 
QuantiTect MAPK1 Primer Hs_MAPK1_1_SG QuantiTect Primer Assay (QT00065933) 
QuantiTect MAPK3 Primer HS_MAPK3_1_SG QuantiTect Primer Assay (QT00000532) 
  
pCMV-HA/myc SeqF 5'- GAT CCG GTA CTA GAG GAA CTG AAA AAC-3' 
pCMV-HA/myc SeqR 5'- TTA CAA ATA AAG CAA TAG CAT CAC-3' 
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pCATrMP-953 953bp of the rabbit MMP-9 
promoter; CAT  
this study 
pCATrMP-717 717bp of the rabbit MMP-9 
promoter; CAT 
this study 
pCATrMP-493 493bp of the rabbit MMP-9 
promoter; CAT 
this study 
pCATrMP-144 144bp of the rabbit MMP-9 
promoter; CAT 
 
this study 
pCATrMP AP-1 proximal mt 1550bp of the rabbit MMP-9 
promoter with a mutated proximal 
AP-1 site; CAT 
this study 
pCATrMP AP-1 distal mt 1550bp of the rabbit MMP-9 
promoter with a mutated distal AP-
1 site; CAT 
this study 
pCATrMP ETS 1 mt 1550bp of the rabbit MMP-9 
promoter with a mutated ets 1 
site; CAT 
this study 
pCATrMP ETS 2 mt 1550bp of the rabbit MMP-9 
promoter with a mutated ets 2 
site; CAT 
this study 
pCATrMP-1225 E47mt 1225bp of the rabbit MMP-9 
promoter with a mutated E47 site; 
CAT 
this study 
pCATrMP-1225 MyoD mt 1225bp of the rabbit MMP-9 
promoter with a mutated MyoD 
site; CAT 
this study 
pCATrMP-953 E47 mt 953bp of the rabbit MMP-9 
promoter with a mutated E47 site; 
CAT 
this study 
pCATrMP-953 MyoD mt 953bp of the rabbit MMP-9 
promoter with a mutated MyoD 
site; CAT 
this study 
pSG5 SV40 and T7 promoter controlled; 
ampicillin resistence 
Stratagene, La Jolla, CA, 
USA 
pSG5 CRPV E2 CRPV E2; ampicillin resistence Jeckel et al., 2002 
pSG5 CRPV E6 CRPV E6; ampicillin resistence Prof. Iftner, Tübingen 
pSG5 CRPV E7 CRPV E7; ampicillin resistence Prof. Iftner, Tübingen 
pCAThMPFL full length human MMP-9 
promoter; CAT 
this study 
pCAThMP-1785 1785bp of the human MMP-9 
promoter; CAT 
this study 
pCAThMP-1261 1261bp of the human MMP-9 
promoter; CAT 
this study 
pCAThMP-829 829bp of the human MMP-9 
promoter; CAT 
this study 
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pCAThMP-670 670bp of the human MMP-9 
promoter; CAT 
this study 
pCAThMP AP-1 proximal mt full length human MMP-9 promoter 
with a mutated proximal AP-1 site; 
CAT 
this study 
pCAThMP AP-1 distal mt full length human MMP-9 promoter 
with a mutated distal AP-1 site; 
CAT 
 
this study 
pCAThMP E2mt full length human MMP-9 promoter 
with a mutated E2 binding site; 
CAT 
this study 
pMethionine neo neomycin resistence Grant et al., 1997 
pMeth TAM67 TAM67 (truncated c-jun); 
neomycin resistence 
Grant et al., 1997 
pcDNA3 CMV, Sp6, and T7 promoter 
controlled; neomycin and 
ampicillin resistence 
Invitrogen, Karlsruhe, 
Germany 
pcDNA3 ERK1 KR ERK1:ERK1 K71R Dr. A. Behren, Heidelberg 
pcDNA3 ERK2 KR ERK2:ERK2 K52R Dr. A. Behren, Heidelberg 
pcDNA3 MEKK1 Km MEKK1:ERK1 K432A Dr. A. Behren, Heidelberg 
Uro2345 2345bp of the urokinase- 
plaminogen activator promoter 
Blasi et al. 
pCMV-HA CMV promoter controlled; HA-tag 
upstream of MCS 
TakaraBio Europe/Clontech,  
St.- Germain-en-Laye, 
France 
pCMV-HA HPV6bE2 HPV6bE2 this study 
pCMV-HA HPV6bE6 HPV6bE6 this study 
pCMV-HA HPV6bE7 HPV6bE7 this study 
pCMV-HA HPV16E2 HPV16E2 this study 
pCMV-HA HPV16E6 HPV16E6 this study 
pCMV-HA HPV16E7 HPV16E7 this study 
pCMV-HAeGFP eGFP this study 
pCMV-HAeGFP HPV6bE2 eGFP; HPV6bE2 this study 
pCMV-HAeGFP HPV6bE6 eGFP; HPV6bE6 this study 
pCMV-HAeGFP HPV6bE7 eGFP; HPV6bE7 this study 
pCMV-HAeGFP HPV16E2 eGFP; HPV16E2 this study 
pCMV-HAeGFP HPV16E6 eGFP; HPV16E6 this study 
pCMV-HAeGFP HPV16E7 eGFP; HPV16E7 this study 
pCMV-HA HPV16E2 NLS1 HPV16E2:E2 NLS1 mt this study 
pCMV-HA HPV16E2 NLS2 HPV16E2:E2 NLS2 mt this study 
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pCMV-HA HPV16E2 NESmt HPV16E2:E2 NESmt this study 
pCMV-HA HPV16E2 NESdel HPV16E2:E2 NESdel this study 
pCMV-HA HPV16E2 NLSdel HPV16E2:E2 NLSdel this study 
pCMV-HA HPV16E2 I73A HPV16E2:E2 I73A this study 
pCMV-HA HPV16E2 
307/307 
HPV16E2:E2 306/307 this study 
pCMV-HAeGFP HPV16E2 
NLS1 
eGFP; HPV16E2:E2 NLS1 mt this study 
pCMV-HAeGFP HPV16E2 
NLS2 
eGFP; HPV16E2:E2 NLS2 mt this study 
pCMV-HAeGFP HPV16E2 
NESmt 
eGFP; HPV16E2:E2 NESmt this study 
pCMV-HAeGFP HPV16E2 
NESdel 
eGFP; HPV16E2:E2 NESdel this study 
pCMV-HAeGFP HPV16E2 
NLSdel 
eGFP; HPV16E2:E2 NLSdel this study 
pCMV-HAeGFP HPV16E2 
I73A 
eGFP; HPV16E2:E2 I73A this study 
pCMV-HAeGFP HPV16E2 
306/307 
eGFP; HPV16E2:E2 306/307 this study 
pCMV dsRED-Express CMV promoter controlled dsRed; 
kanamycin/neomycin resistence 
TakaraBio Europe/Clontech,  
St.- Germain-en-Laye, 
France 
 
 
2.1.4 Cell Lines and Bacterial Strains 
 
Table 4: List of cell lines and bacterial strains. 
Name  Supplier 
E. coli XL1-Blue chemically competent 
bacteria 
Stratagene, La Jolla, CA, 
USA 
E. coli NEB5alpha chemically competent 
bacteria 
New England Biolabs, 
Frankfurt/Main, Germany 
Rab-9 spontaneously immortalized 
rabbit epithelial cell line 
ATCC 
C33A HPV-negative human 
cervical cancer cell line 
ATCC 
HaCat spontaneously immortalized 
human keratinocytes 
Prof. Dr. A. Alonso, DKFZ 
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HPV16 E6 HPV16 E6 immortalized 
primary human 
keratinocytes 
Prof. Dr. F. Roesl, DKFZ 
HPV16 E7 HPV16 E7 immortalized 
primary human 
keratinocytes 
Prof. Dr. F. Roesl, DKFZ 
HPV16E6/E7 HPV16 E6 and E7 
immortalized primary 
human keratinocytes 
Prof. Dr. F. Roesl, DKFZ 
NIH 3T3 spontaneously immortalized 
mouse fibroblasts 
DSMZ, Braunschweig, 
Germany 
 
 
2.1.5 Antibodies  
 
Table 5: List of antibodies. 
Antibody Supplier Species Dilution 
Actin Santa Cruz (sc-1616) rabbit polyclonal 1:100 (IF) 
1:3000 (WB) 
c-jun Cell Signaling Technology 
(#9165) 
rabbit polyclonal 1:1000 
Phospho-c-Jun (Ser63) 
II 
Cell Signaling Technology 
(#9261 ) 
rabbit polyclonal 1:1000 
c-fos Cell Signaling Technology 
(#2250)  
rabbit polyclonal 1:1000 
c-Raf Cell Signaling Technology 
(#9422) 
rabbit polyclonal 1:1000 
GFP Roche (11 814 460 001) mouse monoclonal 1:1000 
Monoclonal Anti-HA 
Clone HA-7 
Sigma (H 9658) mouse monoclonal 1:100 (IF) 
1:3000 (WB) 
JNK Santa Cruz (sc-474)  rabbit polyclonal 1:2000 
Phospho-SAPK/JNK 
(Thr183/Tyr185) 
Cell Signaling Technology 
(#9251) 
rabbit polyclonal 1:1000 
SV40 KT3 tag (KT3) Santa Cruz (sc-58664)  mouse monoclonal 1:100 (IF) 
1:1000 (WB) 
MMP-9 (C-20) Santa Cruz (sc-6840)  goat polyclonal 1:1000 
p38 MAPK Santa Cruz (sc-535-G)  goat polyclonal 
 
1:3000 
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Phospho-p38 MAP 
Kinase 
(Thr180/Tyr182) 
Cell Signaling Technology 
(#9211) 
rabbit polyclonal 1:1000 
p44/42 MAP Kinase Cell Signaling Technology 
(#9102) 
rabbit polyclonal 1:3000 
Phospho-p44/42 MAP 
Kinase 
(Thr202/Tyr204) (E10) 
Cell Signaling Technology 
(#9106)  
mouse monoclonal 1:1000 
goat αnti-mouse IgG- 
HRP 
Santa Cruz (sc- 2005) goat 1:3000- 
1:5000 
donkey αnti-rabbit 
IgG-HRP 
Santa Cruz (sc- 2313) donkey 1:3000- 
1:5000 
donkey αnti-goat IgG, 
HRP 
Santa Cruz (sc- 2020) donkey 1:3000- 
1:5000 
IRDye 680 Conjugated 
Goat Anti-Mouse IgG  
926-32220 
Licor 
goat polyclonal 1:10000 
PF-780 Goat Anti-
Rabbit IgG  
PK-PF780-AK-R1 
PromoKine 
goat polyclonal 1:2000 
IRDye 800 Conjugated 
Donkey Anti-Goat IgG 
926-32214 
Licor 
donkey polyclonal 1:10000 
AlexaFluor488 Goat 
Anti-Mouse IgG (H+L) 
A-11001 
Molecular Probes 
mouse  1:500 
Cy3-conjugated 
AffiniPure Goat Anti-
Rabbit IgG (H+L) 
111-165-003  
Dianova (Jackson 
ImmunoResearch) 
rabbit 1:200 
Cy3-conjugated 
AffiniPure Rabbit Anti-
Goat IgG, Fc Fragment 
Specific 
305-165-008 
Dianova (Jackson 
ImmunoResearch) 
goat 1:200 
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2.2 MOLECULAR BIOLOGY 
 
2.2.1 Amplification of DNA 
 
DNA was amplified using a BioRad Mini Thermocycler (BioRad, Munich, Germany) using 
either Taq (New England Biolabs, Frankfurt/Main, Germany), Pfu (Fermentas, St. Leon-
Rot, Germany), or Hot-Start FidelITaq Polymerase (USB, Staufen, Germany) with 
supplied buffer according to the manufacturers’ recommendations and dNTPs purchased 
from Fermentas. Amplification was carried out according to the protocol described below. 
 
94°C 2 min  
94°C 30 sec  
* 45 sec 25-35x 
72°C 30 sec –  
90 sec# 
 
72°C  5 min  
4°C ∞  
* Annealing temperature was usually about 2°C below melting temperature of the 
respective primers used or determined by gradient PCR.  
# Elongation time was dependent on the length of the desired fragment.  
 
2.2.2 Agarose Gel Electrophoresis  
 
Gel electrophoresis was carried out in horizontal electrophoresis chambers (BioRad, 
Munich, Germany). 1.0 – 2.0 % agarose gels were prepared by dissolving UltraPure 
Agarose (Invitrogen, Karlsruhe, Germany) in 1x Tris-acetate-EDTA (TAE) buffer and 
adding of 10µl of ethidium bromide (1mg/ml) to each 150ml of agarose solution. 10x 
loading buffer was added to the DNA samples for subsequent electrophoresis at 100V for 
30 to 75 minutes depending on DNA size and gel concentration. After electrophoresis, 
DNA fragments were visualized under UV light (302 nm) and photographed. 
 
2.2.3 Construction of a DNA-library 
 
A DNA library was constructed using the GenomeWalker Kit (Clonetech, Saint-Germain-
en-Laye, France). DNA from a New Zealand White rabbit’s skin was digested using the 
supplied endonucleases following the manufacturer’s manual. Amplification of the DNA 
region of interest was carried out using the supplied adaptor-specific primers (AP1 and 
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AP2) and gene-specific primers (MMP9neu4 und MMP9revnested2). The PCR protocols 
used were the two-step protocols suggested in the manual: 
 
PCR1: 
primer 1: AP1 
primer 2: MMP9neu4 
 
94°C 2 sec 
 
72°C 3 min 
 
5x 
   
94°C 2 sec 
 
67°C 3 min 
 
20x 
   
67°C 4 min  
4°C ∞  
 
PCR2: 
primer 1: AP2 
primer 2: MMP9revnested2 
 
 
94°C 2 sec 
 
72°C 4 min 
 
7x 
   
94°C 2 sec 
 
67°C 4 min 
 
32x 
   
67°C 4 min  
4°C ∞  
 
 
2.2.4 DNA-Sequencing 
 
Sequencing of the major part of the MMP-9 promoter was conducted at GATC Biotech 
(Constance, Germany). The remainder of the sequence was analyzed by V. Benes (EMBL 
Heidelberg, Germany) after cloning of the fragment into the pCAT3 Basic reporter gene 
vector (Promega). 
 
All other constructs and mutants were sequenced for confirmation at GATC Biotech 
(Constance, Germany). 
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2.2.5 Cloning       
 
2.2.5.1 Restriction Reactions 
 
Restriction of vector and insert DNAs was carried out using restriction endonucleases 
from Fermentas or New England Biolabs and was performed in the supplied buffers and 
at appropriate temperatures. Vectors were digested for 1 to 2 hours whereas fragments 
were usually incubated overnight at room temperature.   
 
2.2.5.2 Alkaline-Phosphatase Treatment 
 
After digestion, vectors were treated with 1 µg Calf-intestinal Alkaline-Phosphatase 
(CIAP; Fermentas, St. Leon-Rot, Germany) for dephosphorylation of ends.  
  
 2.2.5.3 Ligation Reactions 
 
Ligations were performed using the Ligate-IT Rapid Ligation Kit (USB, Staufen, Germany) 
with a 3:1 insert:vector ratio as determined by gel electrophoresis for all samples 
otherwise following the supplied protocol. 
 
2.2.6 Transformation of chemically competent bacteria 
  
2.2.6.1 Preparation of chemically competent E.coli 
 
For preparation of chemically competent cells, the following solutions were used: 
 
Medium YT** 
 
8 g  Bacto-Trypton 
8 g  Bacto-Hefeextrakt 
5 g NaCl 
 
Add H2Obidest to yield 1 liter 
Adjust pH to 7.5 
 
Following autoclavation the medium was supplemented with: 
 
20 ml    1 M MgSO4   
10 ml    1 M KCl    
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TFB I 
 Stock solution in 200 ml 
30 mM potassium acetate  0.5  M 12 ml 
50 mM mangane chloride 1  M 10 ml 
100 mM rubidium chloride 0.5  M 40 ml 
10 mM calcium chloride 0.5  M 4  ml 
15 % glycerol    30 ml 
H2Obidest   104 ml 
Adjust pH to 5.8 
Store at 4°C 
 
TFB II 
 Stock solution in 50 ml 
10 mM NaMOPS 0.1 M 5 ml 
75 mM calcium chloride  0.5 M 7.5 ml 
10 mM rubidium chloride 0.1 M 1 ml 
15 % glycerol    7.5 ml 
H2Obidest   29  ml 
Adjust pH to 7.0 
Store at 4°C 
 
2-2.5 ml YT** medium were inoculated with a single E.coli NEB5α-colony and incubated 
overnight on a rotary shaker (200 rpm). Two 5 ml tubes with YT** were each inoculated 
with 50 µl of the overnight culture at 37°C and 200 rpm. At an OD600 of 0.8 each culture 
was added to a new flask containing 100 ml pre-warmed YT**-medium. This main 
culture was incubated on a rotary shaker until it reached an OD600 of 0.4 -0.55 and then 
was transferred to sterile and chilled 50 ml centrifuge tubes and kept on ice for 5 
minutes. After centrifuging at 4,000 g at 4°C for 5 minutes, the supernatant was 
decanted and the tubes placed back on ice. 10 ml of TFB I were added to each of the 
tubes and cells were resuspended before centrifuging under the previously mentioned 
conditions. The supernatant was again decanted, the cells were carefully resuspended in 
2 ml TFB II, and aliquoted into 50 µl fractions which were shock-frozen in liquid nitrogen 
and stored at -80°C until further use. 
 
 2.2.6.2 Transformation of cells 
 
For transformation, aliquoted competent cells were thawed on ice. 10-100 ng of DNA 
were added to the cells and the mixture was incubated on ice for 30 minutes. After 
incubation, the mixture was heat-shocked in a thermo-block at 42°C for 2 minutes and 
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returned to ice for another 5 minutes. 200µl of LB medium were added and the cells were 
subsequently incubated for 1 hour at 37°C and 250rpm. 100-200µl of the cell suspension 
were then plated into LB agar containing the appropriate antibiotic and incubated 
overnight at 37°C. 
 
2.2.7 Mutagenesis 
 
Site-directed mutagenesis was carried out using the Site-directed mutagenesis Kit 
(Stratagene, Amsterdam, The Netherlands) or the Site-directed mutagenesis XL Kit 
(Stratagene, Amsterdam, The Netherlands) according to the manufacturer’s 
recommendations. 
 
2.2.8  Plasmid Purification 
 
Plasmid purification was carried out using either the QIAprep Spin Miniprep Kit or the 
QIAGEN Plasmid Midi Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
protocols. 
 
2.2.9 Isolation of genomic DNA from cells and tissue samples 
 
Genomic DNA from cultured cells and tissue samples was isolated using the DNeasy 
Blood & Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. 
 
2.2.10 RNA Isolation 
 
Isolation of RNA from cultured cells was conducted using the RNeasy Mini Kit (Qiagen, 
Hilden, Germany) following the supplied protocol including an On-Column DNase 
digestion using the RNase-Free DNase Set (Qiagen, Hilden, Germany). 
 
2.2.11 Quantification of DNA and RNA Samples 
 
The amount of DNA or RNA present in samples was determined using a NanoDrop 
Biophotometer (PeqLab Biotechnologie, Erlangen, Germany). 
 
2.2.12 Reverse Transcription (RT)- PCR 
 
For reverse transcription, the amount of RNA of samples to compare was equalized with 
RNase-free water. RT-PCR was carried out using the High-Capacity cDNA Reverse 
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Transcription Kit (Applied Biosystems, Darmstadt, Germany) according to the 
manufacturer’s protocol using the supplied reagents without addition of RNase inhibitor.  
 
2.2.13 Quantitative End-point PCR 
 
Quantitative End-point PCR was carried out as described in 2.2.1 using the below 
depicted protocol and cycle numbers as appropriate for the respective gene.  
 
94°C 5 min  
94°C 30 sec  
60 (67)°C 30 sec 30-34 x 
72°C 25 sec  
72°C 5 min  
4°C ∞  
67°C in the annealing step were used for rabbit DNA. 
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2.3 CELL BIOLOGY 
 
2.3.1 General Cell Culture  
 
All cells were maintained in the appropriate culture medium at 37°C and 5% CO2. 
 
2.3.2 Cell Culture Media and Supplements 
 
DMEM  
High Glucose (4.5 g/l) with L-Glutamine 
(PAA, Cölbe, Germany) 
for cultivation of C33A, HaCat, and NIH3T3 
cells; 
supplemented with 10% FBS and 1% AbAm 
DMEM/Ham’s F-12  
with L-Glutamine (PAA, Cölbe, Germany) 
for cultivation of Rab-9 cells; 
supplemented with 10% FBS and 1% AbAm 
Keratinocyte SFM (Invitrogen, Karlsruhe, 
Germany) 
supplemented with EGF and BPE as supplied 
with the Kit (Invitrogen, Karlsruhe, 
Germany) 
AntibioticAntimycotic (AbAm) 100x conc 
(Invitrogen, Karlsruhe, Germany) 
for supplementation of media 
Foetal Bovine Serum Standard Quality EU 
approved (PAA, Cölbe, Germany) 
for supplementation of media 
 
2.3.3 Thawing and Freezing of Cells 
 
Frozen cells were thawed quickly in a 37°C water bath and transferred to petridishes 
containing the appropriate culture medium. After 12-18 hours medium was exchanged to 
remove the remainder of DMSO from the freezing medium.  
For freezing, cells were grown in cell culture flasks to approximately 90% confluency, 
washed in PBS and trypsinized. The resulting cell suspension was centrifuged at 1,600 g 
for 4 minutes and the pellet resuspended in freezing medium (regular cell culture 
medium containing 20% FBS and 20% DMSO or PromoCell CryoSFM). The cell 
suspension was then transferred to cryo-vials. These were then placed inside a cell 
freezer (Nunc) to allow for a constant cooling rate of 1°C per minute and stored at -80°C.  
 
2.3.4 Transfection 
 
Transfection-grade plasmid DNA was obtained by plasmid preparation as previously 
described (2.2.8.). All transfection reactions were prepared in OptiMEM (Invitrogen, 
Karlsruhe, Germany). The amount of medium supplied varied with the well size used. 
Generally, 12-well plates (Corning) were used and medium was exchanged from regular 
  EXPERIMENTAL PROCEDURES 
 
 
 -35- 
growth medium to serum-free antibiotic-free DMEM with L-Glutamine (PAA, Cölbe, 
Germany) just prior to addition of the transfection reaction. Medium was changed back to 
regular growth medium 5 hours after transfection. 
 
2.3.4.1 Transfection of DNA 
 
Transfection reactions were prepared by providing two microcentrifuge tubes per reaction 
containing 100µl OptiMEM per well to be treated (12-well format). DNA was added to one 
of the tubes in an amount determined by previous optimization. Lipofectamine2000 
(Invitrogen, Karlsruhe, Germany) was added to the second tube at either 1µl per well 
(Rab-9), 2µl per well (C33A), or 4µl per well (NIH3T3).  
 
 2.3.4.2 Transfection of siRNA 
 
Transfection of siRNAs was conducted with Oligofectamine (Invitrogen, Karlsruhe, 
Germany) following the manufacturer’s recommedations for the amounts of medium to 
be used. Oligofectamine was used at 3µl with 3µl of 20nM siRNA per reaction. 
 
2.3.5 Nuclear staining 
 
For nuclear staining prior to microscopic investigation or fixation for immunofluorescence, 
cells were incubated with Hoechst-33342 Dye (Sigma-Aldrich, Munich, Germany) for 30 
minutes to 1 hour at 37°C, 5% CO2. 
 
2.3.6 Preparation of whole cell lysates 
 
Whole cell lysates were prepared by rinsing the cells with ice-cold PBS and adding CST 
Cell lysis buffer (Cell Signaling Technologies, Frankfurt/Main, Germany) with PMSF added 
just before addition to the cells. Plates were then incubated at 4°C for 5 minutes and 
subsequently cell lysates were transferred to a microcentrifuge tube and centrifuged at 
13,000rpm for 10 minutes to remove the cell debris.  Where necessary, lysates were 
additionally homogenized using a QiaShredder (Qiagen, Hilden, Germany). 
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2.4 BIOCHEMISTRY 
 
2.4.1 Concentration of proteins 
   
For concentration of proteins, protein solutions were applied to Amicon columns (Amicon 
Ultra YM-30; MILLIPORE Corporation, USA) and centrifuged at 5,000 rpm until the 
desired concentration was reached. 
 
2.4.2 Protein determination 
 
Protein concentrations were determined using the Bicinchinonic Acid (BCA) Assay (Pierce, 
Darmstadt, Germany). For this, 20µl of Solution B were added to each ml of Solution A. 
10µl of the protein solution to be determined were added to 990µl of the mixture of 
Solutions A and B and incubated at 37°C and 250rpm for 30 minutes prior to measuring 
absorbance at 562nm.  
 
2.4.3 Immunoprecipitation 
 
For immunoprecipitation, ProteinA/G Plus Agarose (Santa Cruz Biotechnologies, 
Heidelberg, Germany) was used. Cell lysates were equalized in protein content and 15µl 
of the 50% agarose slurry were added to a maximum of 500µl lysate and the solution 
was precleared in a rotator at 4°C for 1 hour. The solution was centrifuged in a tabletop 
centrifuge at 2,500 rpm for 5 minutes and subsequently the supernatant was transferred 
to a new microcentrifuge tube. 1 µg of required antibody was added to the lysate and 
incubated for 1 hour at 4°C. After incubation with the antibody 20µl of agarose slurry 
were added and the solution subsequently incubated in a rotator at 4°C overnight. 
Immunoprecipitates were then collected at 2,500 rpm for 5 minutes and the supernatant 
was carefully discarded. Pellets were washed 4x with 1.0 ml PBS each time repeating the 
centrifugation step above. After the final wash, the supernatants were again discarded 
and the pellets resuspended in 40 µl 2x sample buffer, boiled for 2 minutes and agarose 
beads pelleted by centrifugation. Samples were analysed using SDS-PAGE (2.4.5). 
 
2.4.4 ELISA  
 
2.4.4.1 Preparation of cell lysates for CAT-ELISA 
 
Cells for CAT-ELISA (Roche, Mannheim, Germany) were lysed according to the 
manufacturer’s manual with the lysis buffer supplied with the kit.  
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2.4.4.2 CAT-ELISA 
 
Cell debris was pelleted at 13,000 rpm for 5-10 minutes prior to protein determination by 
BCA. The amount of lysate used was equalized according to protein concentration and 
ELISA carried out according to the supplied protocol (Roche, Mannheim, Germany). The 
absorption was determined at 492 nm using an Anthos 2010 MTP-Reader (Anthos 
Mikrosysteme GmbH, Krefeld, Germany). 
 
2.4.5 SDS-PAGE 
 
SDS-PAGE was performed according to Laemmli [1970]. Solutions needed were stored at 
4°C until further use. 
 
Acrylamide stock solution (PAA Protogel TM): 
 
Acrylamide-/Bisacrylamide solution 30%: 0.8% (Roth, Karlsruhe, Germany) 
 
 
 
Running buffer (1x): 
 
Sample buffer (4x): 
 
Glycin 0.2 M Tris/HCl pH 6.9 0.25 M 
Tris 0.025 M SDS 8  % 
SDS 1 % Glycerol 40  % 
add H2Obidest to yield 1 liter   Mercaptoethanol 20  % 
   Bromphenol blue 0.002  % 
 
For native gels, solutions without SDS and/or mercaptoethanol were used. 
 
 
 
 
 
 
“Upper Tris”: 
 
“Lower Tris”: 
Tris/HCl pH 6.9 0.5  M Tris/HCl pH 8.9 1.5  M 
SDS  0.4  % SDS 0.4  % 
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Composition of SDS polyacrylamide gels (0.75 mm thickness): 
for 2 gels collection gel separation gel 
H2Obidest 6.2 ml 5 ml 
“Upper Tris” 2.5 ml - 
“Lower Tris” - 3.75 ml 
PAA 1.3 ml 6.25 ml 
APS (10%) 75 µl 125 µl 
TEMED 10 µl 15 µl 
Ammoniumpersulphate (APS) was prepared as a stock solution of 10% APS in H2Obidest and stored at -20°C. 
 
For non-native SDS-PAGE, proteins were diluted in 4x SDS sample buffer and boiled for 
10 minutes. Electrophoretic separation of the proteins was carried out at 100V.  
 
Protein standard: 
PageRuler Prestained Protein Ladder (#SM0671, Fermentas, St. Leon-Rot, Germany): 10 
bands; 10-170 kDa 
 
For use, the marker was heated to 70-95°C for 2 minutes and transferred to ice 
immediately after heating. 
Application: 3-5 µl to SDS gel. 
 
2.4.6 Gelatin Zymography 
 
For gelatin zymography, an SDS-gel containing gelatin was prepared according to the 
protocol given below. Probes were loaded onto the gel with 10x Zymo buffer (2.5 M Tris-
HCl pH 6.8, 50% SDS, 0.5% bromphenol blue, 2 ml glycerol, H2Obidest to 10 ml) and the 
gel was run at 90V for approximately one hour when the running buffer front was at the 
bottom of the gelatin gel. This was then washed in 2.5% Triton-X 100 for 2 hours to 
remove all SDS and hence allow the proteins to refold. The buffer was then exchanged 
for Incubation Buffer (50 mM Tris-HCl pH 7.6, 10 mM CaCl2 x 2H2O, 50 mM NaCl, 0.05% 
Brij-35) which allows the proteins (gelatinases) to degrade the gelatin. Incubation was 
carried out at 37°C overnight with gentle shaking. The gel was then rinsed with cold 
water, stained with Coomassie R250 (Sigma, Munich, Germany), and destained with 40% 
Acetic Acid, 10% Methanol until transparent bands became visible. 
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for 1 gel (1.5 mm) collection gel gelatin gel 
H2Obidest 6.2 ml 3.85 ml 
“Upper Tris” 2.5 ml -  
“Lower Tris” -  2.6 ml 
PAA 1.3 ml 2.5 ml 
Gelatin (5%) -  1 ml 
APS (10%) 75 µl 100 µl 
TEMED 10 µl 6 µl 
 
2.4.7 Protein Transfer (Western Blot) 
 
After SDS-PAGE, proteins were transferred from the gel to an Immobilon-P PVDF 
membrane (Millipore, Schwalbach, Germany) using a BioRad MiniProteanII Wet Blot 
Chamber (BioRad, Munich, Germany). Prior to transfer, filter paper and membranes were 
cut equalling approximately the size of the gel. The membrane was activated in methanol 
for 10 seconds before being equilibrated in transfer buffer (0.2M Glycin, 0.025M Tris, 
20% Methanol). For blotting, sponges and filter paper were soaked in transfer buffer and 
everything was set up according to the manufacturer’s recommendations. Transfer time 
was between 60 to 90 minutes at 80 – 100V. 
 
2.4.8 Immunodetection of proteins 
 
Following the transfer, membranes were blocked for 1 hour at room temperature in 
either 5% skim milk in TBST or 5% BSA in TBST as suggested for the respective 
antibody. If no protocol was supplied by the manufacturer, 5% skim milk in TBST was 
used.  
After blocking, the membrane was washed three times for 5 minutes in TBST. The 
primary antibodies were prepared with the dilutions given under 2.1.4 in either of the 
blocking buffers and membranes incubated with the antibody solutions overnight at 4°C 
with gentle agitation. Unbound antibody was then washed off the membrane with TBST 
(3x 5 minutes) followed by the addition of the secondary antibody in the respective 
buffer and incubation for 1 hour at room temperature on an orbital shaker (35-40 rpm). 
Again, unbound antibody was removed from the membrane by washing 3x for 5 minutes.  
The membrane was then transferred to a clean tray; ECL Plus reagent (GE Healthcare, 
Munich, Germany) was mixed according to the manufacturer’s protocol and added by 
pipetting it on top of the membrane several times. Without letting it dry, the membrane 
was then transferred to seran wrap and into an x-ray chamber. HyperFilm ECL Films (GE 
Healthcare, Munich, Germany) were exposed to the membrane under red light in a 
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darkroom for appropriate time and subsequently developed in a HyperProcessor (GE 
Healthcare, Munich, Germany). 
 
2.4.9 Immunofluorescence 
 
 2.4.9.1 Coating of Coverslips 
 
For coating, coverslips were rinsed with 100% ethanol and air-dried for a few seconds. 
They were then placed into 12-well or 24-well plates depending on their size and washed 
with PBS. After washing coverslips were coated with an appropriate volume of coating 
medium (described below) for one hour at room temperature. This was followed by 
washing with PBS and drying for 1 hour at room temperature. 
 
Coating medium 
PBS without Ca2+ and Mg2+ 50 ml 
Acetic acid 0.02 % 
Rat-tail Collagen I 50 µg/ml 
 
As soon as the coverslips were dried, cells were plated at the desired density and treated 
as needed. 
 
 2.4.9.2 Fixation of Cells 
 
24 hours after seeding or transfection, cells plated on coverslips were fixed with either 
ice-cold methanol for 20 minutes on ice or with 4% Paraformaldehyde in PBS for 15 
minutes at room temperature followed by permeabilization with 0.25% Triton-X 100 in 
PBS for 20 minutes. 
 
 2.4.9.3 Antibody Staining 
 
Following fixation, the coverslips were washed in PBS and blocked in 1% BSA in PBST for 
30 minutes. The primary antibody was then diluted in 1% BSA in PBST and applied to the 
coverslips which have been transferred to a humidity chamber. The coverslips were 
incubated with the primary antibody for one hour and then washed 2 to 3 times in PBS 
before applying the secondary antibody solution (in blocking buffer) for another hour. 
After incubation with the secondary antibody, coverslips were washed 2 times with PBS 
and rinsed in water before transferring them upside-down onto slides using VectaShield 
mounting medium (Linaris Biologische Produkte, Wertheim, Germany). 
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2.5 MICROSCOPY 
 
2.5.1 Bright-field microscopy 
 
Regular analysis of cells using bright-field microscopy was performed using a Hund 
Wilovert AFL inverse fluorescense microscope (Hund, Wetzlar, Germany) at a 
magnification of 10x. 
 
2.5.2 Fluorescence microscopy 
 
Microscopic investigation of fluorescently stained and/or eGFP expressing cells was 
carried out using a Zeiss AxioImager PlanAPOCHROMAT microscope (63x,1.4 oil), an  
AxioCam MRm R3, and the software AxioVision 4.7 (all Carl Zeiss, Jena, Germany) at the 
Zeiss Demonstation Center at the DKFZ in Heidelberg or using a Nikon 90i upright 
automated microscope at 40x magnification, a D1QM camera and the EZ-2.3-Viewer 
software (all Nikon, Düsseldorf, Germany) at the Nikon Center (Uni Heidelberg). 
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3 RESULTS 
 
3.1 THE RABBIT MATRIX-METALLOPROTEINASE 9 PROMOTER 
 
The cottontail rabbit papillomavirus (CRPV) induced papillomas and carcinomas in the 
New Zealand White rabbit (NZW) serve as a model system for the development and 
progression of epithelial lesions induced by papillomaviruses. Mutations in the 
transactivation domain of CRPV E2 in the context of the virus genome have been 
described to abolish the formation of papillomas and carcinomas in the rabbit model. 
Hence, it could be concluded that the E2 protein is of importance in the initial steps of 
CPRV-induced tumorigenesis. In a study by Behren et al. (2005) it was discovered that in 
CRPV E2-induced lesions and carcinomas the expression of matrix-metalloproteinase 9 
(MMP-9) is upregulated (Figure 9) when compared to uninfected rabbit skin.  
 
 
 
 
 
Furthermore, in-vitro experiments have led to the observation that HPV31 E2 as well as 
CRPV E2 are both able to activate a minimal human MMP-9 promoter fragment in 
reporter-gene assays (Behren et al., 2005). In order to determine in detail the means by 
which the CRPV E2 protein achieves the induction of MMP-9 and to investigate whether 
this observation is comparable to a function of human high-risk papillomavirus E2, the 
first aim of this study was to sequence and clone the rabbit MMP-9 promoter. 
 
3.1.1 Cloning the rabbit MMP-9 promoter 
 
To determine the sequence of the rabbit MMP-9 promoter a library of genomic DNA 
isolated from New Zealand White rabbit skin was constructed according to the work-flow 
described in Figure 10. The genomic DNA was extracted from the skin and subsequently 
Figure 9: MMP-9 expression in rabbit skin lesions. Gelatin zymography of lysates prepared from 
papillomavirus-induced lesions of NZW rabbit skin showed expression of MMP-9 (Courtesy of A. Behren). 
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digested with restriction enzymes. Adapter-sequences were then annealed to the ends of 
the resulting fragments and a PCR was performed using a primer recognizing part of the 
adapter sequence and a gene-specific primer designed to bind within the rabbit MMP-9 
gene of which the sequence is known. The largest DNA fragment obtained from this PCR 
reaction was subjected to nested-PCR and resulted in an 1872bp fragment which was 
subsequently sequenced (see attachment 1). 
 
 
 
 
 
 
The rabbit MMP-9 promoter sequence was aligned to the human MMP-9 promoter 
(Attachment 2). The N-terminal ~500bp and the proximal ~800bp showed a similarity of 
76 and 77% whereas the intermediate ~600bp yielded only 13% homology (Figure 11). 
Furthermore, the CA-repeat located between -154 and -109bp in the human that is also 
found in the mouse promoter was not present in the rabbit promoter sequence. 
  
 
 
Figure 10: Schematic Work-flow scheme of the Clontech GenomeWalker Kit. The library was 
constructed using extracted genomic DNA from rabbit skin, followed by digestion, annealing of adapter 
sequences, and nested PCR. 
Figure 11: Schematic alignment of the 
rabbit and human MMP-9 promoter. The 
rabbit MMP-9 promoter sequence was aligned 
to the human promoter sequence using Clustal 
W. The similarities between separate parts of 
the promoter are illustrated here. 
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3.1.2 Regulatory parts of the rabbit MMP-9 promoter 
 
The promoter then was cloned into the reporter-gene vector pCAT3 Basic for further 
characterization. This vector expresses the gene for chloramphenicol acetyltransferase 
(CAT) upon activation of the promoter cloned in front of it. To identify the minimal 
promoter fragment required for activation, the promoter sequence was continously 
shortended by 300bp off the 5’-end (Figure 12) and all of these deletion constructs were 
also cloned into the reporter-gene vector pCAT3 Basic. 
 
 
 
 
 
 
In order to test the functionality of the constructs, the MMP-9 promoter was activated 
using the tumor-inducer PMA, and the activation was analyzed by CAT-ELISA. 
Beforehand, the ability of PMA to induce MMP-9 expression in-vitro and the optimal 
amount of PMA required for induction was determined by addition of the reagent to the 
cells in serum-free medium and subsequent gelatin zymography of the obtained 
supernatants. It was hence shown that PMA is able to induce the expression of MMP-9 in 
Rab-9 cells and determined that the best concentration of PMA for activation experiments 
is 50nM (Figure 13). Therefore, all further experiments requiring PMA-induction were 
carried out using this concentration. 
 
 
 
Figure 13: PMA-induced MMP-9 
expression in Rab-9 cells. 
Expression of MMP-9 was induced by 
addition of different concentrations of 
PMA to the cells. Supernatants were 
collected 24 hours after treatment, 
concentrated, equalized for protein 
content and subjected to gelatin 
zymography. Concentrations of PMA 
were 10, 25, 50, and 100nM as 
indicated by labelling of lanes. 
Figure 12: Schematic illustration of rabbit MMP-9 promoter deletion constructs. Deletion mutants 
were constructed with lengths of 1550bp, 1225bp, 953bp, 717bp, 480bp, and 144bp. The constructs are 
illustrated here with relative lengths. The dark blue part indicates the start of the coding region. 
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The CAT-ELISA results of PMA-stimulated rabbit promoter deletion constructs showed an 
average activation of 48-to 65-fold ±10 of the promoter constructs which were 717bp or 
longer. PMA was unable to induce activation of the promoter for constructs 493bp and 
144bp in length (Figure 14a). The PMA solvent DMSO was added to replicas of the 
transfection and served as a negative control. No activation could be detected upon CAT-
ELISA with these lysates (Figure 14b). 
 
 
 
 
 
 
 
 
Activation of the promoter deletion constructs by CRPV E2 showed a difference when 
compared to PMA-stimulation. While promoter constructs of 1872bp, 1550bp, 1225bp, 
(a) 
(b) 
Figure 14: Reporter-gene assays of rabbit MMP-9 promoter deletion constructs stimulated with 
PMA. CAT-expression in reporter-gene transfected cell lysates was detected by CAT-ELISA after stimulation 
with PMA (a) or DMSO, which served as negative control for PMA (b). Statistics were done by Students T-
Test *, P≤0.05; **, P≤0.01; ***, P≤0.005 as compared to the empty vector control. Bars show mean value 
± SD from three independent experiments in triplicate. 
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and 717bp length showed activation levels to be 2.5- to 3.7-fold, and constructs with less 
than 717bp could not be activated as was previously seen for PMA, there was a significant 
decrease in activation levels for the 953bp promoter fragment which showed an activation 
of only 1.7-fold ± 0.3 (Figure 15). This led to the suggestion of a repressor element to be 
situated between -953bp and -717bp of the promoter which was further investigated later 
in this study. 
 
 
 
 
 
 
 
The induction of MMP-9 expression after transient transfection of Rab-9 rabbit cells with 
CRPV E2 was also investigated on mRNA and protein level. Expression of MMP-9 on 
protein level was determined by gelatin zymography which yielded a perceptible 
difference between the empty vector control and the CRPV E2-transfected cells (Figure 
16a). The expression of MMP-9 mRNA was investigated using semi-quantitative RT-PCR of 
transcribed cDNA obtained from rabbit cells after transfection with empty vector or CRPV 
E2, respectively (Figure 16b).  
 
Figure 15: Reporter-gene assays of rabbit MMP-9 promoter deletion constructs induced by co-
transfection with CRPV E2. CAT-expression was observed after co-transfection of Rab-9 cells with CRPV 
E2 and promoter deletion constructs. Statistics were done by Students T-Test *, P≤0.05; **, P≤0.01; ***, 
P≤0.005 as compared to the empty vector control. Bars show mean value ± SD from three independent 
experiments in triplicate. 
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The transcription-factor binding sites (TFBSs) within the MMP-9 promoter were then 
identified using the programs TFSEARCH and TESS. The thresholds were set to 85% 
similarity. The results of the programs were examined and TFBSs outlined by both 
programs were combined in a table (Table 7).  
         
          
Transcription 
factor 
Position in the 
rabbit promoter 
Transcription 
factor 
Position in the  
human promoter 
TATA -47 to -42 TATA -48 to -44 
SP1 -67 to -76 SP1 -64 to -73 
AP-1 -103 to -97 AP-1 -98 to -92 
NFkB -134 to -124 CA-repeat -154 to -109 
SP1 -185 to -176   
  NFkB -350 to -341 
  SP1 -504 to -495 
NFkB -469 to -461   
AP-1 -480 to -474 AP-1 -556 to -550 
PEA3 -487 to -482 PEA3 -563 to -558 
NFkB -547 to -538 NFkB -623 to -614 
  NFkB -636 to -628 
NFkB -703 to -695   
  E2 -1120 to -1109 
SP1 -985 to -976   
  AP-1 -1485 to -1475  
  AP-1 -1681 to -1673 
  TATA -1800 to -1787 
Figure 16: Induction of MMP-9 expression on 
protein and mRNA level. Supernatants of cells 
transfected with either pSG5 alone (1) or pSG5 
CRPV E2 (2) were subjected to gelatin 
zymography. The level of MMP-2 serves as a 
loading control (a). mRNA isolated from transiently 
transfected cells was transcribed to cDNA and 
quantitative PCR was conducted at 60°C (70°C for 
MMP-9) for 36 cycles. H2O served as negative 
control (b).  
Table 7: List of transcription factor binding sites and their positions. 
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As the transcription factor AP-1 has been shown to play a role in the transcriptional 
activation of MMP-9 (Sato and Seiki, 1993), the two AP-1 binding sites found in the rabbit 
MMP-9 promoter sequence were each deleted individually by site-directed mutagenesis. 
Subsequent reporter-gene assays of cells which were transfected with the mutant 
promoter constructs and stimulated with PMA showed a highly significant decrease of 
almost 100% in the activation of the reporter gene upon deletion of the distal AP-1 
binding site (pCAT3 rMP-1550 AP-1d mt) (Figure 17a). Deletion of the proximal binding 
site (pCAT3 rMP-1550 AP-1p mt) led to a decrease of 45 ± 5%, which was also 
significant. Parallel reporter-gene assays of cells co-transfected with the mutant rabbit 
promoter constructs and CRPV E2 also yielded a significant reduction of reporter-gene 
activation, however, in this case the reduction of promoter activation was equal for both 
AP-1 sites and yielded 40% of wild-type activity (Figure 17b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  RESULTS 
 
 
 -49- 
 
 
 
 
 
 
 
 
 
 
 
 
Besides the transcription factor complex AP-1, we examined the role of the ets 
transcription factor which has been shown to be of importance in tumorigenesis. There 
Figure 17: Effect of the AP-1 binding sites within the rabbit MMP-9 promoter on activation.  The 
relative activation of the MMP-9 promoter constructs containing mutations in either of the putative AP-1 
transcription factor binding sites was investigated after induction by PMA (a) or co-transfection with CRPV 
E2 (b). The activation of the wild-type MMP-9 promoter was set to 100%. The schematic illustration shows 
the AP-1 binding sites mutated within the context of the promoter (light blue). The dark blue part signifies 
the start of the coding region (c). Statistics were done by Students T-Test *, P≤0.05; **, P≤0.01; ***, 
P≤0.005 as compared to the wild-type promoter. Bars show mean value ± SD from three independent 
experiments in triplicate. 
(a) 
(b) 
(c) 
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are two ets binding sites (termed PEA3) located within the promoter sequence of -717 
and -480bp, and both were deleted individually to investigate the involvement of ets in 
promoter activation. It could be seen from reporter-gene assays conducted with these 
mutants that neither of the ets binding sites had an influence on CRPV E2-mediated 
activation (Figure 18).  
 
 
 
 
 
 
 
 
 
 
 
In order to prove the possibility for a repressor element binding within the promoter 
region between -953bp and -717bp, the respective ~250bp were more closely examined 
for the presence of potential repressive elements. Two candidates, an E47 and a MyoD 
binding site have been identified, which have been shown to act as repressors in other 
studies (REF). After mutation of these sites in the context of both, the 1225bp and the 
953bp promoter, the constructs were again used in reporter-gene assays. It could be 
observed that while mutation of either of the binding sites within the 1225bp promoter 
did not lead to a significant change in activation by E2 (Figure 19a), mutation of the E47 
binding site within the 953bp fragment resulted in a substantial increase in activation by 
about 85% ± 26% (Figure 19b), which raised activation levels almost to the level of the 
1225bp promoter construct (Figure 19c).  
 
Figure 18: Effect of the ets binding sites within the rabbit MMP-9 promoter on activation. The 
relative activation of the MMP-9 promoter constructs containing mutations in either of the putative ets 
transcription factor binding sites was investigated after induction by PMA (a) or co-transfection with CRPV 
E2 (b). The activation of the wild-type MMP-9 promoter was set to 100%. The schematic illustration shows 
the ets binding sites mutated within the context of the promoter (light blue). The dark blue part signifies the 
start of the coding region (c). Statistics were done by Students T-Test *, P≤0.05; **, P≤0.01; ***, 
P≤0.005 as compared to the wild-type promoter. Bars show mean value ± SD from three independent 
experiments in triplicate. 
(a) (b) 
(c) 
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To show the comparability of the rabbit model to the human system, analogous 
experiments were conducted to the ones described above, utilizing the human MMP-9 
promoter. Firstly, the ideal concentration of PMA to induce MMP-9 expression in C33A 
human cervical cancer keratinocytes has been determined by gelatin zymography. The 
results showed that here, a concentration of 25 nM yielded the best induction (Figure 20). 
For better comparison, 50 nM were used here as was for induction of rabbit cells.  
 
(a) 
(b) 
(c) 
Figure 19: Effects of MyoD 
and E47 binding sites in the   
-1225 and -953 promoter 
deletion constructs. The effect 
of CRPV E2-induction on 
promoter constructs containing 
mutations introduced into the -
1225 (a) and -953bp (b) 
promoters was studied by CAT-
ELISA. Wild-type promoters were 
set to 100%, activation of 
mutants is given relative to the 
wild-types. (c) shows the fold 
activation of -1225 and -953bp 
promoters and mutants to allow 
for visualization of the effect of 
the -953bp promoter mutants 
compared to the activation level 
of the wild-type -1225bp 
promoter. 
Statistics were done by Students 
T-Test *, P≤0.05; **, P≤0.01; 
***, P≤0.005 as compared to 
the empty vector control (a), (b). 
Bars show mean value ± SD from 
three independent experiments in 
triplicate. 
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A full length fragment of the human MMP-9 promoter which corresponded in the 
alignment to the full length rabbit MMP-9 promoter construct was cloned into the same 
reporter-gene vector (pCAT3 Basic). Three 5'-deletion constructs spanning similar regions 
as the constructs of the rabbit MMP-9 promoter were constructed (Figure 21).  
 
 
 
 
 
 
 
Reporter-gene assays carried out with all human MMP-9 promoter constructs showed an 
activation of the reporter-gene of 3.3 – 4.3-fold when induced with PMA (Figure 22a). 
Induction with HPV16 E2 led to a 2.5 – to 2.9-fold activation of promoter fragments of 
1261bp and larger while for the 829bp promoter fragment an induction of 1.3-fold ± 0.2 
could be observed (Figure 22b). A small but perceptible increase in the amount of MMP-9 
mRNA in pCMV-HA HPV16 E2 transfected cells could be detected by semi-quantitative RT-
PCR (Figure 23).  
 
Figure 20: PMA-induced MMP-9 expression in C33A cells. Expression of MMP-9 was induced by 
addition of different concentrations of PMA to the cells. Supernatants were collected 24 hours after 
treatment, concentrated, equalized for protein content and subjected to gelatin zymography. Concentrations 
of PMA were 10, 25, 50, and 100nM as indicated by labelling of lanes. 
Figure 21: Illustration of the human MMP-9 promoter deletion constructs. Human deletion 
fragments were constructed which cover similar regions as the rabbit MMP-9 promoter deletion mutants. 
They are depicted here in relative lengths with the dark blue parts indicating the beginning of the coding 
region. 
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Figure 22: Activation of the human MMP-9 promoter by PMA and HPV16 E2. Activation of the human 
promoter constructs was determined by CAT-ELISA of cell lysates prepared 48 hours after transfection with 
either promoter deletion constructs induced by PMA (a) or co-transfected with HPV16 E2 (b). Statistics were 
done by Students T-Test *, P≤0.05; **, P≤0.01; ***, P≤0.005 as compared to the empty vector control. 
Bars show mean value ± SD from three independent experiments in triplicate. 
Figure 23: Induction of MMP-9 mRNA 
expression by HPV16 E2. MMP-9 expression was 
induced by transient transfection of C33A cells with 
pCMV-HA HPV16 E2. The level of mRNA was 
detected by semi-quantitative RT-PCR at 36 cycles, 
H2O served as negative control. 
(a) 
(b) 
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Of special interest in conjunction with the activation of the human full length MMP-9 
promoter with HPV16 E2 was the presence of an E2-binding site at -1120 to -1109bp. 
This E2-binding site was deleted by site-directed mutagenesis as has been desribed for 
binding sites for AP-1 and ets before. It can be seen from the results of subsequent 
reporter-gene assays that this E2BS has no influence on the activation of the human 
MMP-9 promoter by E2 (Figure 24).  
 
 
 
 
 
 
 
 
 
 
 
Analogous to the experiments conducted with the rabbit promoter, the role of AP-1 was of 
interest in the activation of human promoter as well. The AP-1 binding sites found in the 
human promoter are homologous to the ones in the rabbit promoter in both, position and 
sequence. It has been shown previously in studies by Behren et al. (2005) that the 
proximal AP-1 binding site in the human promoter is of importance in E2-mediated 
activation. Therefore, an AP-1 decoy was used in this study to confirm the involvement of 
the AP-1 complex in promoter activation. A decoy is a synthetic oligonucleotide that 
resembles the transcription factor consensus sequences and hence competes for binding 
of the transcription factor with consensus sequences in target genes. Co-transfection of 
Figure 24: Effect of the E2-binding site on promoter activation. The relative activation of the MMP-9 
promoter constructs containing mutations in the putative E2 binding site was investigated after co-
transfection with CRPV E2. The activation of the wild-type MMP-9 promoter was set to 100% (a). The 
schematic illustration shows the E2 binding site mutated within the context of the full length promoter (light 
blue). The dark blue part signifies the start of the coding region (b). Statistics were done by Students T-Test 
*, P≤0.05; **, P≤0.01; ***, P≤0.005 as compared to the wild-type promoter. Bars show mean value ± SD 
from three independent experiments in triplicate. 
(a) 
(b) 
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the AP-1 decoy with the human MMP-9 promoter and HPV16 E2 resulted in a decrease in 
activation by 40 ± 4% (Figure 25) as compared to the control decoy.  
 
 
 
 
 
 
 
 
3.1.3  Involvement of c-Jun in E2-mediated promoter activation 
 
It has been described in the introduction that the transcription factor AP-1 is a dimeric 
complex which consists of members of the jun- and fos- families. To determine the 
involvement of the often in cancer upregulated component c-Jun in the complex required 
for activation of the MMP-9 promoter by PMA, CRPV E2, and HPV16 E2, the 
transactivation-deficient c-jun mutant TAM67 (REF) was used for co-transfection with the 
respective promoters and papillomavirus E2 proteins or PMA. PMA-mediated activation of 
the promoter was shown to be decreased to a level of 15% ± 2% as compared to the 
empty vector control (Figure 26a). CRPV E2-mediated promoter activation was decreased 
to 22% ± 2% (Figure 26b), and the activation of the promoter by HPV16 E2 was lowered 
to 46% ± 4% when compared to the empty vector control (Figure 26c).  
Figure 25: Influence of the transcription factor AP-1 in HPV16 E2-mediated MMP-9 promoter 
activation. Cells transfected with the full length MMP-9 promoter, HPV16 E2, and either AP-1 decoy or 
control decoy were lysed and the effect of the decoy on promoter activation was investigated. The result of 
the control decoy experiment was set to 100%. Statistics were done by Students T-Test *, P≤0.05; **, 
P≤0.01; ***, P≤0.005 as compared to the control decoy. Bars show mean value ± SD from three 
independent experiments in triplicate. 
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Figure 26: Effect of TAM67 on promoter activation. Rabbit cells were transfected with full length 
rabbit MMP-9 promoter, and either TAM67 expressing vector or empty vector control. Cells were induced 
either by addition of PMA (a), or co-transfection with CRPV E2 (b). Human keratinocytes were 
transfected with full length human MMP-9 promoter and TAM67-vector or control vector, and induced 
with HPV16 E2 (c). The effect of the transactivation-deficient c-jun construct TAM67 on promoter 
activation was investigated. The activation of the empty vector control was set to 100%. Statistics were 
done by Students T-Test *, P≤0.05; **, P≤0.01; ***, P≤0.005 as compared to the empty vector 
control. Bars show mean value ± SD from three independent experiments in triplicate. 
(a) 
(b) 
(c) 
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3.2 SIGNAL-TRANSDUCTION PATHWAYS IN E2-MEDIATED MMP-9 PROMOTER 
ACTIVATION 
 
AP-1 is mainly regulated by the activity of MAP-kinases and MMP-9 induction has been 
found to rely on the ERK and the p38 pathway. To determine the MAP-Kinase signal-
transduction cascades involved in mediating the activation of MMP-9, chemical inhibitors 
were used. SB203580 is a pyridinyl imidazole that specifically inhibits p38 by binding 
withing its ATP-pocket. SP600125 specifically inhibits c-jun N-terminal protein kinase 
(JNK), and PD098059 ablates the phosphorylation of ERK by MEK. Firstly, the 
functionality of the inhibitors was determined. For the SAP-Kinases p38 and JNK cells 
were pre-treated with the respective inhibitor for 24 hours and kinases were activated by 
addition of 10µg/ml anisomycin for 30 minutes. Cells were then lysed and lysates 
investigated for the appropriate products using Western blotting, and for p38 in addition 
by using a PathScan p38 ELISA (Figure 27a,c,d). For PD098059, cells were also pre-
treated with the inhibitor for 24 hours and subsequently ERK was activated by addition of 
50nM PMA. Cell lysates were obtained and equalized for protein amount and analyzed via 
Western blotting (Figure 27b).  
 
 
 
 
 
Figure 27: Inhibitor controls. The phosphorylation states of downstream targets of the MAP-Kinases JNK 
(a), ERK (b), and p38 (c, d) were determined after induction with anisomycin (JNK, p38) or PMA (ERK) and 
treatment with the respective inhibitors by western blotting or ELISA. 
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As the controls confirmed the functionalities of the respective inhibitors, these were then 
used in reporter-gene assays with CRPV E2 (Figure 28) and HPV16 E2 (Figure 29). It was 
found that in both systems, use of the MEK inhibitor PD098059 led to a highly significant 
decrease in activation potential of the papillomavirus E2 proteins of about 70% for CRPV 
E2 and 60% for HPV16 E2. The p38 inhibitor showed little effect in the rabbit system and 
led to a decrease in promoter activation of about 20% in the human system. SP600125 
had no effect on the E2-mediated activation of the promoter in either system.  
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Effect of chemical inhibitors on CRPV E2-induced activation of the rabbit MMP-9 
promoter. Cells were transfected with full length MMP-9 promoter constructs and CRPV E2 and treated with 
chemical inhibitors of the MAP-kinases ERK (PD), JNK (SP), and p38 (SB). Treatment with the inhibitor 
solvent DMSO served as negative control and was set to 100%. Statistics were done by Students T-Test *, 
P≤0.05; **, P≤0.01; ***, P≤0.005 as compared to the DMSO-treated control. Bars show mean value ± SD 
from three independent experiments in triplicate. 
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The phosphorylation state of the respective MAP-kinase in transfected cells was thus 
investigated more closely by western blotting. It could be seen that transfection with E2 
led to an elevated level of pERK and its downstream-target pELK (Figure 30). 
 
 
        
 
 
 
 
The impact of the inhibitors on the transcriptional activation of MMP-9 was also 
investigated in the human system on the mRNA level. Using semi-quantitative RT-PCR, a 
Figure 29: Effect of chemical inhibitors on HPV16 E2-induced activation of the human MMP-9 
promoter. Cells were transfected with full length MMP-9 promoter constructs and HPV16 E2 and treated 
with chemical inhibitors of the MAP-kinases ERK (PD), JNK (SP), and p38 (SB). Treatment with the inhibitor 
solvent DMSO served as negative control and was set to 100%. Statistics were done by Students T-Test *, 
P≤0.05; **, P≤0.01; ***, P≤0.005 as compared to the DMSO-treated control. Bars show mean value ± SD 
from three independent experiments in triplicate. 
Figure 30: Phosphorylation levels of ERK and its downstream target ELK in Papillomavirus E2 
transfected cells. Phoshorylation levels werde detected by western blotting of cell lysates obtained after 
transfection with CRPV E2 (a) or HPV16 E2 (b) or their respective empty vectors.  
.  
(a) (b) 
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differential expression of MMP-9 was detected in cells transiently transfected with either 
pCMV-HA HPV16 E2 or the empty vector and treated with the inhibitors described above 
(Figure 31). 
 
 
 
 
 
 
 
Further, human cells were transiently co-transfected with the human MMP-9 promoter 
construct, HPV16 E2 and dominant negative mutants of ERK1 and ERK2. Subsequent 
reporter-gene assays led to the observation that co-expression of both of these deletion 
mutants had a similar effect and resulted in a reduction of activation of about 50% as 
compared to the empty vector control (Figure 32).  
 
Figure 31: mRNA levels of transiently HPV16 E2 transfected human keratinocytes after treatment 
with chemical inhibitors. MMP-9 expression was induced by transient transfection of C33A cells with 
pCMV-HA HPV16 E2. Cells were treated with chemical inhibitors to investigate their effect on mRNA 
expression. The level of mRNA was detected by semi-quantitative RT-PCR at 36 cycles, H2O served as 
negative control. 
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3.3 ACTIVATION OF THE MMP-9 PROMOTER BY EARLY PROTEINS E6 AND E7 
 
The early proteins E6 and E7 have been shown to be the transforming proteins in HPVs. 
Most importantly for the present study, E7 has been decribed to interact with the subunits 
of the transcription factor AP-1. Hence it was of interest, whether E6 and E7 also have the 
ability to induce the activation of the MMP-9 promoter.  
The reporter-gene vector previously constructed and described was used for transient co-
transfection with expression-vectors carrying the cDNA for either CRPV E2, CRPV E6, or 
CRPV E7 or HPV16 E2, HPV16 E6, or HPV16E7. Reporter-gene assays carried out in the 
rabbit system showed an activation of 9-fold ± 2 for CRPV E6, and an induction of 4-fold 
± 0.4 for CRPV E7 (Figure 35a). On the contrary, neither HPV16 E6 nor HPV16 E7 was 
able to induce the expression of the reporter-gene above the level of the empty vector 
control (Figure 35b). 
 
Figure 32: Effect of dominant-negative mutants of ERK1, ERK2, and MEKK1 on human MMP-9 
promoter activation. Cells were transfected with the full length human promoter construct, HPV16 E2, and 
dominant-negative mutants of ERK1, ERK2, and MEKK1. Results are given in % as relative to the empty 
vector control. Statistics were done by Students T-Test *, P≤0.05; **, P≤0.01; ***, P≤0.005 as compared 
to the empty vector control. Bars show mean value ± SD from three independent experiments in triplicate. 
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3.4 ACTIVATION OF THE UROKINASE-PLASMINOGEN ACTIVATOR (UPA) 
 
Besides MMP-9, there are many other proteases upregulated by similar mechanisms 
during tumorigenesis. It has been shown that the urokinase-plasminogen activator (uPA), 
is often upregulated in parallel to MMP-9 in cancers. Furthermore, uPA, when bound to its 
receptor uPAR, converts plasminogen to plasmin which is then able to cleave the pro-form 
of MMP-9 and thereby activates it. We therefore investigated whether any of the early 
proteins E2, E6, or E7 of HPV16 has an impact on the expression of uPA.  
Figure 35: Activation of the MMP-9 prmomoter constructs by papillomavirus early proteins. Rab-9 
cells were transfected with the rabbit MMP-9 promoter and CRPV E2, E6, or E7 (a). Human keratinocytes 
were transfected with the full length human MMP-9 promoter and HPV16 E2, E6, or E7, respectively (b). 
Statistics were done by Students T-Test *, P≤0.05; **, P≤0.01; ***, P≤0.005 as compared to the empty 
vector control. Bars show mean value ± SD from three independent experiments in triplicate.  
(a) 
(b) 
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The level of uPA mRNA was investigated using semi-quantitative RT-PCR.  An increase in 
uPA expression could be detected in transiently HPV16 E2 transfected cells when 
compared to the empty vector control (Figure 36).  
 
 
 
 
 
 
As uPA has been previously been described to be activated by MAP-Kinases, the uPA 
mRNA levels of transiently HPV16 E2 transfected cells treated with chemical inhibitors of 
the MAPKs p38, JNK, and ERK were investigated by semi-quantitative RT-PCR. It could be 
observed that the amount of uPA mRNA was diminished upon treatment with (Figure 37). 
 
 
 
 
 
 
 
Figure 36: Induction of uPA mRNA expression by HPV16 E2. Urokinase expression was induced by 
transient transfection of C33A cells with pCMV-HA HPV16 E2 or empty vector control. The level of mRNA 
was detected by semi-quantitative RT-PCR at 36 cycles, H2O served as negative control. 
Figure 37: uPA mRNA levels of transiently HPV16 E2 transfected human keratinocytes after 
treatment with chemical inhibitors. Urokinase expression was induced by transient transfection of C33A 
cells with pCMV-HA HPV16 E2 or empty vector control. Cells were treated with chemical inhibitors for 48 
hours to investigate their effect on uPA mRNA expression. The level of uPA mRNA was detected by semi-
quantitative RT-PCR at 36 cycles, H2O served as negative control. 
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Using an uPA promoter constructs of 2345bp, reporter-gene assays were thus carried out. 
It was found that HPV16 E2 was able to activate the uPA-promoter 4-fold, whereas both, 
transfection with HPV16 E6 and HPV16 E7 resulted in a 3-fold activation (Figure 38).  
 
 
 
 
 
 
 
 
3.5 LOCALIZATION STUDIES 
 
It has been reported by Blachon et al. (2005) that high-risk human papillomavirus E2 as 
opposed to low-risk HPV is able shuttle between nucleus and cytoplasm. The study shows 
an influence of the cytoplasmic localization on the induction of apoptosis by high-risk HPV. 
It was hence of interest for the present work if a difference in localization of the E2 
protein has an impact on the induction of MMP-9 expression.  
 
 
3.5.1 Construction of eGFP-tagged HPV16 E2 and localization studies 
 
 
In order to carry out localization studies with both, HPV16 E2 and HPV6b E2, the proteins 
were tagged with eGFP to allow for easy visualization. The proteins also obtained a HA-
tag at the N- and a KT3-tag at the C-terminus to determine the integrity of the proteins 
(Figure 39). 
 
Figure 38: Activation of the uPA promoter by HPV early proteins E2, E6, and E7. Human 
keratinocytes were transfected with the urokinase-plasminogen activator promoter and HPV16 E2, E6, or 
E7, respectively (b).  Statistics were done by Students T-Test *, P≤0.05; **, P≤0.01; ***, P≤0.005 as 
compared to the empty vector control. Bars show mean value ± SD from three independent experiments in 
triplicate. 
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Localization studies revealed that while eGFP-HPV6b E2 was strictly nuclear, eGFP-HPV16 
E2 was present in the nucleus as well as within the cytoplasm (Figure 40). Addition of 
leptomycin B an inhibitor of exportin-1 receptor (CRM1)-dependent nuclear export 
resulted in solely nuclear localization of eGFP-HPV16 E2 (Figure 41). 
 
 
 
 
 
 
Figure 39: Schematic illustration of the tagged E2 proteins cloned into pCMV-HA. The CMV-
promoter of the vector is geiven in dark blue, the HP-tag is also present in the vector and given here in dark 
green. eGFP is cloned in-frame with the HA-tag and depicted in light green, followed by the HPV E2 cDNA in 
light blue and the KT3-tag in purple. 
Figure 40: Immunofluorescence of fibroblasts transfected with the eGFP-tagged proteins. Cells 
were stained with DAPI (DNA) and actin was detected with an anti-actin primary and Cy3-labelled anti-
rabbit secondary antibody. GFP was detected by autofluorescence.  
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The ability of the eGFP-tagged HPV16 E2 to induce the acitvation of the MMP-9 promoter 
upon co-transfection was also determined and compared to the untagged HPV16 E2. It 
could be observed that although activation was less than that of wt-E2, the difference was 
significant (Figure 42). Hence further investigation of the effects of the mutant E2 
proteins on promoter activation was carried out using proteins without eGFP-tag.  
To investigate the regulatory sequences impacting the localization of HPV16 E2 as 
compared to HPV6b E2, the respective protein sequences of HPV16 E2 and HPV6b E2 
have been compared. It was found that HPV16 E2 contains only one nuclear localization 
sequence (NLS) as compared to HPV6b E2, but also shows a nuclear export sequence 
(NES) which is not found in the low-risk type. Hence, different approaches were used to 
investigate the potential role of E2 localization in MMP-9 promoter activation. Firstly, 
either one of the two NLS found in HPV6b E2 were introduced to HPV16 E2, resulting in 
the mutant constructs HPV16 E2 NLS1 and HPV16 E2 NLS2. Secondly, the NES found in 
HPV16 E2 was mutated (HPV16 E2 NESmt) or deleted (HPV16 E2 NESdel). Using 
immunofluorescence and the eGFP-tagged E2 mutants, the localization of the mutant 
proteins was determined.  
Figure 41: Localization of HPV16 E2eGFP protein after treatment with leptomycin B. Localization of 
the eGFP-tagged proteins was determined via eGFP autofluorescence. 
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3.5.2 Impact of additional NLS sites on localization 
 
Immunofluorescence of the NLS mutant HPV16 E2 eGFP fusion proteins (Figure 43) 
revealed that both of the mutants containing an additional NLS site were localized solely 
within the nucleus (Figure 44). 
 
 
 
 
Figure 42: Effect of the eGFP-tag on activation of the human MMP-9 promoter. Cells were 
transfected with the full length human MMP-9 promoter construct and either HPV16 E2 or eGFP-tagged 
HPV16 E2. Wild-type E2 was set to 100% and relative activation was determined for the eGFP-tagged 
protein. Statistics were done by Students T-Test *, P≤0.05; **, P≤0.01; ***, P≤0.005 as compared to 
untagged E2. Bars show mean value ± SD from three independent experiments in triplicate. 
Figure 43: Illustration of the mutations introduced into the E2 protein. Two NLS sites found in low-
risk HPV types but absent from high-risk types were separately introduced into HPV16 E2. The original 
sequences are given in this illustration, the amino acid changes are indicated in bold underneath. 
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In reporter-gene assays, the ability of the mutant proteins to activate the MMP-9 
promoter was investigated. Here, the NLS mutant constructs showed no significant 
decrease in their activation potential of the MMP-9 promoter (Figure 45).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44: Immunofluorescence of NLS mutants. Cells were stained with DAPI (DNA) and actin was 
detected with an anti-actin primary and Cy3-labelled anti-rabbit secondary antibody. GFP was detected by 
autofluorescence. 
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3.5.3 Influence of the NES site on protein localization 
 
The nuclear export sequence (NES) found in high-risk HPV types such as HPV16 was 
mutated in a way that NetNES 1.1, a program detecting NES sequences, did no longer 
recognize an export signal. A second mutant was constructed in which the whole NES 
sequence was deleted (Figure 46). 
 
 
 
 
Figure 45: Effect of the introduced NLS sites on activation of the MMP-9 promoter. Cells were 
transfected with the full length human MMP-9 Promoter and HPV E2 or the HPV16 E2 NLS mutants. 
Promoter activation by wild-type E2 was considered to be 100%. Statistics were done by Students T-Test *, 
P≤0.05; **, P≤0.01; ***, P≤0.005 as compared to wild-type E2. Bars show mean value ± SD from three 
independent experiments in triplicate. 
Figure 46: Illustration of the mutations introduced to the NES sites. The NES sites present only in 
high-risk HPV types was mutated (NES mt) or deleted (NES del) in HPV16 E2. The original sequences are 
given for HPV16 E2 NES mt, the amino acid changes are indicated in bold underneath. The deleted amino 
acids in HPV16 E2 NES del are indicated. 
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The HPV16 E2 NESmt construct was still present in both, cytoplasm and nucleus, 
however, presence in the nucleus was far more frequent than with the wild-type 
construct. The HPV16 E2 NESdel was found to be solely nuclear (Figure 47). 
Deletion of the complete NES sequence resulted in an insignificant decrease of promoter 
activation, however, the HPV16 E2 NESmt construct showed a significant decrease in 
activation potential (Figure 48). A similar decrease in promoter activation has previously 
been described for the transactivation-deficient HPV31 E2 mutant I73A in a study by 
Behren et al. (2005) and was confirmed here and which is of nuclear location as deterined 
by immunofluorescence (Figure 49). 
    
     
 
 
 
 
 
 
Figure 47: Immunofluorescence of NES mutant E2 proteins. Cells were stained with Hoechst 33342 
(DNA) and actin was detected with an anti-actin primary and Cy3-labelled anti-rabbit secondary antibody. 
GFP was detected by autofluorescence. 
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Figure 48: Effect of mutations in the NES site on MMP-9 promoter activation. Cells were transfected 
with the full length human MMP-9 Promoter and HPV E2 or the HPV16 E2 NES mutants. Promoter activation 
by wild-type E2 was considered to be 100%. Statistics were done by Students T-Test *, P≤0.05; **, 
P≤0.01; ***, P≤0.005 as compared to wild-type E2. Bars show mean value ± SD from three independent 
experiments in triplicate. 
Figure 49: Transactivation-deficient E2 mutant I73A. Cells were stained with Hoechst 33342 (DNA) 
and actin was detected with an anti-actin primary and Cy3-labelled anti-rabbit secondary antibody. GFP was 
detected by autofluorescence (a). Cells were transfected with the full length human MMP-9 Promoter and 
HPV E2 or the HPV16 E2 I73A mutant. Promoter activation by wild-type E2 was considered to be 100% (b). 
Statistics were done by Students T-Test *, P≤0.05; **, P≤0.01; ***, P≤0.005 as compared to wild-type E2. 
Bars show mean value ± SD from three independent experiments in triplicate. 
(a) 
(b) 
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Hence, it was interesting to investigate whether the E2 protein of HPV6b which, as 
previously described, remains strictly within the nucleus, is also able to activate the 
human MMP-9 promoter in reporter-gene assays. As it turns out, HPV6b E2 induces a 4.2-
fold activation on the promoter (Figure 50) and is therefore a potent activator of the 
MMP-9 promoter. 
 
 
 
 
 
 
3.5.4 The NLS deletion mutant 
 
The results obtained for the E2 protein of low risk type HPV6b suggest that the E2 
proteins interact intranuclearly with proteins that then lead to activation of the MMP-9 
promoter. To investigate this hypothesis, a mutant was created in which the only NLS 
found in HPV16 E2 is rendered non-functional (Figure 51a) resulting in a mainly 
cytoplasmic localization of the protein (Figure 51b,c). When this mutant was used in 
reporter-gene assays with the human MMP-9 promoter, a CAT-expression of only 40% of 
that of wildtype HPV16 E2 was observed which is significantly lower than wildtype HPV16 
E2 activation (Figure 52).  
 
Figure 50: Activation of the human MMP-9 promoter by HPV6b E2. Cells were transfected with HPV6b 
E2 and the human MMP-9 promoter and lysates obtained were subjected to CAT-ELISA. Statistics were done 
by Students T-Test *, P≤0.05; **, P≤0.01; ***, P≤0.005 as compared to the empty vector control. Bars 
show mean value ± SD from three independent experiments in triplicate. 
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(a) 
(b) 
Figure 51: NLS mutant construct and localization. The NLS site found in all HPV types was deleted 
from HPV16 E2 by site-directed mutagenesis. The original sequences are given in this illustration, the amino 
acid changes are indicated in bold underneath (a). Cells were stained with Hoechst 33342 (DNA) and actin 
was detected with an anti-actin primary and Cy3-labelled anti-rabbit secondary antibody. GFP was detected 
by autofluorescence (b). Enlargement of the merged picture shown in b (c). 
(c) 
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A mutation previously described to be deficient in DNA-binding is located within the same 
region as the NLS sequence found in HPV16 E2 is the 306/307 mutation described for 
HPV31 in Behren et al., 2005. This mutation was introduced into the HPV16 E2 protein 
and it could be observed that this mutant had a similar effect on promoter activation as 
was described for HPV31 E2 protein in the above study. Immunofluorescence of the eGFP-
tagged mutant showed a distribution of the protein throughout the cell but more 
frequently within the cytoplasm as was previously observed for wild-type E2 (Figure 53). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52: Effect of HPV16 E2 NLS deletion on MMP-9 promoter activation. Cells were transfected 
with the full length human MMP-9 Promoter and HPV E2 or the HPV16 E2 NLS deletion mutant. Promoter 
activation by wild-type E2 was considered to be 100%. Statistics were done by Students T-Test *, P≤0.05; 
**, P≤0.01; ***, P≤0.005 as compared to wild-type E2. Bars show mean value ± SD from three 
independent experiments in triplicate. 
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Figure 53: DNA-binding deficient E2 mutant 306/307. Cells were stained with Hoechst 33342 (DNA) 
and actin was detected with an anti-actin primary and Cy3-labelled anti-rabbit secondary antibody. GFP was 
detected by autofluorescence (a). Cells were transfected with the full length human MMP-9 Promoter and 
HPV E2 or the HPV16 E2 306/307 mutant. Promoter activation by wild-type E2 was considered to be 100%. 
Statistics were done by Students T-Test *, P≤0.05; **, P≤0.01; ***, P≤0.005 as compared to wild-type E2. 
Bars show mean value ± SD from three independent experiments in triplicate. 
(a) 
(b) 
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4 DISCUSSION 
 
 
4.1 INDUCTION OF MMP-9 PROMOTER ACTIVATION BY PAPILLOMAVIRUS E2 OCCURS 
VIA TWO AP-1 BINDING SITES 
 
The expression of proteases has been linked to the initiation and progression of cancer. 
Overexpression of matrix-metalloproteinase 9 has been associated with many cancers 
including tumors of the skin (O’Grady et al., 2007), cervix (da Silva Cardeal et al., 2006), 
colorectal (Mook et al., 2004), and head and neck region (Pacheco et al., 2002). In the 
rabbit animal model for HPV-induced skin tumorigenesis, an enhanced expression of MMP-
9 could be observed in papillomas and carcinomas as opposed to healthy skin (Behren et 
al., 2005). To investigate the mechanism involved in the activation of the rabbit MMP-9 
promoter, the sequence of the rabbit MMP-9 promoter had first to be investigated. 
Therefore, in this study, a 1872bp fragment of the rabbit MMP-9 promoter has been 
isolated and sequenced. Alignment of the obtained rabbit promoter sequence to the 
sequence of the human MMP-9 promoter resulted in the interesting observation that the 
highest similarities between the two promoters are found within the proximal 800bp and 
the distal 500bp, separated by a region of low similarity of about 600bp. 
Although the proximal region of the MMP-9 promoter seems highly conserved among 
species, the CA-repeat which is present within the human and also the mouse MMP-9 
promoter, is absent in the rabbit. The length of the CA-repeat in the human MMP-9 
promoter has been associated with several diseases such as mutiple sclerosis (Nelissen et 
al., 2000; Fiotti et al., 2004), intracranial and abdominal aortic aneurysms (Shimajiri et 
al., 1999; Yoon et al., 1999), and cancer (Huang et al., 2003). It has been descibed in 
the latter study that a shortening of the microsatellite CA-repeat results in a decrease in 
MMP-9 promoter activation and is accompanied by a reduction of invasion in matrigel 
assays. However, the absense of the CA-repeat seems to have no effect on the regulation 
of the rabbit promoter.  
The highly homologous C-terminal region of the promoter has been described to be 
sufficient for rabbit and human MMP-9 promoter activation in-vitro (Fini et al., 1994; REF) 
and is characterized by the presence of two sequence and position conserved AP-1 
binding motifs. A deletion of the proximal AP-1 binding site in the human promoter has 
been described to eliminate basal as well as PMA-induced promoter activity in a variety of 
oncogenically-transformed cell lines (Sato and Seiki, 1993). This result, however, seems 
dependent on cell type, as the inactivation of this AP-1 binding motif led to only a partial 
decrease of promoter activation in fibroblasts (Fini et al., 1994). In this study, it was 
confirmed that PMA-induced activation of the rabbit MMP-9 promoter was completely 
abolished when the proximal AP-1 binding site was mutated. Upon MMP-9 induction by 
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CRPV E2 it could be observed that this mutation resulted in only a partial decrease in 
promoter activation of approximately 60%, a finding that was also obtained when the 
distal AP-1 binding site was deleted. As the rabbit experiments were carried out in Rab-9 
cells, which are a fibroblast cell line, this may be the reason why activation of the MMP-9 
promoter was only partially reduced while previous studies using the truncated human 
MMP-9 promoter in rabbit epithelial cells showed a complete decrease in activation 
(Behren et al., 2005). We could demonstrate that the rabbit -480bp deletion construct 
was neither activated by PMA nor by CRPV E2. This promoter fragment does still contain 
both AP-1 binding sites, however, the distal AP-1 consensus sequence was at the very 
end of the promoter fragment. It has been described that an NFkB consensus element 
and an SP1-like element in the human MMP-9 promoter cooperate with the proximal AP-1 
motif in determining the response to PMA (Sato and Seiki, 1993). In the rabbit promoter, 
however, the corresponding NFkB binding-site is located upstream of the distal AP-1 
binding site (Fini et al., 1994). This may consequently explain the inability of PMA to 
induce the activation of the -480bp rabbit MMP-9 promoter construct.  
An inhibitory effect was observed when the rabbit -953bp promoter construct was induced 
by CRPV E2. This effect was hypothezised to be due to a repressive element binding to 
the fragment between -717bp and -953bp in the rabbit promoter or steric changes in the 
promoter region induced by the absense of an element which would be present upstream 
of -953bp. The repressive effect was abolished upon elongation of the promoter fragment 
to -1225bp. To further investigate this inhibitory effect, the transcription factor binding 
sites positioned between -717bp and -953bp were determined. The binding sites of two 
transcription factors, MyoD and E47 (Chu et al., 1997; Bolós et al., 2003), which have 
been described to have repressive effects have been chosen and mutated within the 
context of both, the -953bp and the -1225bp promoter. It could be observed that upon 
mutation of the E47 binding site, the activation of the -953bp promoter fragment 
increased to the level detected for the -1225bp and the -717bp promoter. The deletion of 
the E47 binding site in the context of the -1225bp promoter fragment showed no 
significant change in activation as compared to the wild-type promoter. Therefore, it can 
be suggested that the repression observed within the -953bp promoter is an artifical 
repression which is caused by the truncation of the promoter and that E47 binding itself 
has no effect on the full length promoter.  
 
4.2 THE AP-1 COMPLEX COMPONENT C-JUN PLAYS AN IMPORTANT ROLE IN 
PAPILLOMAVIRUS E2-INDUCED MMP-9 PROMOTER ACITVATION 
 
Abbarent expression of c-Jun has been shown to be involved in several human cancers 
such as myeloid leukemia (Rangatia, et al., 2003), Hodgkin lymphoma (Mathas et al., 
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2002), and prostate cancer. In head and neck tumors, c-jun expression has been shown 
to correlate with the the expression of the matrix-metalloproteinases 1 and 9 (Pacheco et 
al., 2002). c-Jun negative ras-transformed cells lack many characteristics of ras 
transformation including the ability to induce tumors in nude mice (Johnson et al., 1996). 
Furthermore, ectopical expression of c-Jun in breast cancer cells resulted in a change in 
AP-1 composition and subsequent conversion into a more aggressive cell line and 
additionally also an increase in MMP-9 (Smith et al., 1999). Co-transfection of cells with 
the transactivation-deficient c-jun mutant TAM67 leads to the integration of the TAM67 
into newly forming AP-1 complexes which compete with functional AP-1 complexes for 
binding to the AP-1 binding motifs. Upon binding of a complex containing TAM67, 
transcription of the respective gene cannot progress and is abolished (Grant et al., 1996). 
TAM67 expression has already shown the importance of c-Jun in the growth of non-small 
cell lung cancer cells (Shimizu et al., 2008). Furthermore, TAM67 can abrogate an 
oncogenic phenotype in Epstein-Barr-Virus (EBV) late-membrane protein-1 (LMP-1) 
positive nasopharyngeal carcinoma (Jin et al., 2007) and inhibits breast cancer growth in-
vivo and in-vitro (Liu et al., 2002). Most interestingly for this study, TAM67 has been 
shown to block HPV16 E7-enhanced tumor progression in mice (Young et al., 2002). 
Here, using co-transfection of TAM67, we were able to observe a highly significant 
inhibition of MMP-9 promoter activation by PMA as well as by CRPV and HPV16 E2. It can 
hence be concluded that c-Jun is a member of the transcription-factor complex binding to 
the MMP-9 promoters which is also confirmed by the above mentioned finding by Smith et 
al. (1999) that an overexpression of c-Jun results in an increase in MMP-9 expression. 
Furthermore, the highly significant ihnhibiton detected is probably due to the fact that  
TAM67 may also inhibit NFkB. The significance of AP-1 in the activation of the promoter 
by E2 was confirmed and taken together with the above mentioned finding that c-Jun is 
involved in HPV16 E7-mediated tumor progression (Young et al., 2002), AP-1 is worth to 
be considered as a target for the prevention of HPV-induced cancers.   
 
4.3 THE MAP-KINASE ERK IS INVOLVED IN E2-MEDIATED MMP-9 PROMOTER 
ACTIVATION  
 
An enhanced activation of ERK has been described in prostate (Zayzafoon et al., 2003), 
ovarian (Al-Ayoubi et al., 2008), and cervical cancers (Branca et al., 2004) among others. 
Its activation is further known to be of importance in the phosphorylation and regualtion 
of c-Jun. It has often been described that the human MMP-9 promoter is regulated by the 
activity of the mitogen-activated protein kinases. Most often this regulation is a result of 
the MAP-kinases ability to induce transcription of members of the transcription factor 
complex AP-1. To investigate the role of the MAP-kinase members JNK, p38, and ERK, in 
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the papillomavirus E2-mediated activation of the MMP-9 promoters, chemical inhibitors 
were added to the cells. In subsequent reporter-gene assays, a highly significant 
decrease in promoter activation could be detected in cells treated with PD098059. As it 
has previously been shown by Behren et al. (2005), this inhibitor was able to block CRPV 
E2-induced invasion in rabbit epithelial cells. Western blot analysis of the phosphorylation 
states of ERK in this study yielded phosphorylation of ERK and its downstream-target ELK 
in both, rabbit and human cell lines after transfection with the respective papillomavirus 
E2 proteins. It has been shown that several viral proteins are involved in the regulation of 
MAPK pathways. The E5 protein of HPV16 is commonly known to activate ERK through its 
upregulation of EGF-receptor signalling (Crusius et al., 1997; Crusius et al., 2000; Cartin 
and Alonso, 2003). The Karposi’s Sarcoma-Associated Herpesvirus (KSHV) induces AP-1 
by activation of primarily ERK and JNK, but to a low degree also by p38 (Xie et al., 2005) 
in contrast to the Hepatitis B Virus HBx protein, which has been described to induce and 
activate AP-1 by via ERK and JNK (Benn et al., 1996).  The LMP-1 protein of EBV, which is 
also known to upregulate MMP-9, has been shown to influence a variety of cellular 
transcription factors such as NFkB and AP-1 (Yoshizaki et al., 1998).  
 
4.4 THE E6 AND E7 PROTEINS OF CRPV BUT NOT HPV16 INDUCE MMP-9 PROMOTER 
ACTIVATION 
 
The E7 protein of human papillomavirus has been desribed to interact with several 
members of the AP-1 complex. Therefore, it may be possible that this protein hence 
influences the expression of AP-1 dependent genes such as MMP-9. Furthermore, it is 
plausible to suggest that the oncogene E6, which has also been shown to interact with 
cellular genes, is also involved in the induction of proteases to promote tumor 
progression, especially as the E2 ORF has been shown to be disrupted after integration of 
the HPV genome in late stages of carcinogenesis. Co-transfection of the human and rabbit 
MMP-9 promoter with the respective early proteins E6 and E7 yielded a difference in 
activation capacity between the HPV and CRPV proteins. While the HPV proteins did not 
induce promoter activation, the CRPV E7 protein resulted in an activation comparable to 
that of E2. CRPV E6 resulted in a 9-fold activation. Previous investigation of the function 
of the CRPV E6 protein by Ganzenmueller et al. (2008) has already shown that the 
protein is different to that of HPV as it does neither bind E6Ap nor induce degradation of 
p53. Here, we were able to describe another difference between HPV and CRPV E6.  
However, the importance of HPV E2 in the induction of human MMP-9 expression in 
infected cells has thus been made even clearer. The question that remain to answer is 
how MMP-9 remains upregulated even after integration of the HPV genome into the host 
cell DNA. As this integration event occurrs only in the late stages of infection it is possible 
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that the activation of the ERK cascade results in an encironment which is favorable for the 
development of lesions and enhanced cellular proliferation. Upon induction of this 
process, the activation of ERK may continue in an autocrine way and thus influence the 
expression of viral (Chan et al., 1990) and cellular genes that are regualted by AP-1.  
 
4.5 THE EARLY PROTEINS E2, E6, AND E7 OF HPV16 ALL AFFECT THE ACTIVATION OF 
THE HUMAN UPA PROMOTER  
 
It has been determined in several studies, that the uPA/uPAR system is involved in the 
establishment and progression of tumors. Upon binding to the receptor, uPA cleaves 
plasminogen to plasmin, which in turn is able to activate several classes of proteins 
including members of the matrix-metalloproteinases. Furthermore, uPA expression has 
been desribed to be acivated by similar means as MMP-9. The uPA promoter has been 
previously characterized and the transcription-factor AP-1 has been described to be of 
importance in the activation of uPA. Futhermore, binding of uPA to uPAR leads to an 
activation of signal-transduction pathways including ERK. As the mechanisms of MMP-9 
and uPA induction are similar and uPA has been shown to be of importance in activating 
MMP-9, it was interesting to determine whether the expression of HPV16 E2, has an effect 
on uPA expression or promoter activation. Experiments with the rabbit uPA promoter 
could not be carried out due to the fact that it is yet unavailable. In human keratinocytes, 
mRNA levels of uPA were detected after transient transfection with HPV16 E2 and an 
increase in the mRNA level of uPA could be detected, which decreased upon addition of 
the ERK inhibitor PD098059 to the transfected cells. Additionally, in reporter-gene assays 
an involvement of the HPV16 early proteins E6 and E7 in uPA promoter activation could 
be observed. This may result in a continued activation of MMP-9 secreted by surrounding 
stromal cells by plasmin in late stages of tumorigenesis, when the viral genome becomes 
integrated. The continued, E2-independent expression of uPA may thus lead to the 
maintenance of a growth-favorable microenvironment. 
 
4.6 THE ROLE OF HPV16 E2 LOCALIZATION IN MMP-9 PROMOTER ACTIVATION 
 
In a study by Blachon et al. (2005) it was shown that E2 of high-risk HPV-types is located 
within the nucleus and cytoplasm of an infected cell. It is able to move freely between the 
two compartments due to the presence of a nuclear export signal (NES) and a nuclear 
localization sequence (NLS). Low-risk HPV E2 on the other hand is present solely within 
the nucleus. As opposed to high-risk E2, low-risk E2 proteins contain three NLSs but no 
NES. In their study, Blachon et al. (2005) associated the localization of the proteins with 
the induction of apoptosis as can be detected in high-risk HPV infection. Using HPV16 E2 
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mutants, we set out to investigate the role of E2 localization on the protein’s ability to 
activate the human MMP-9 promoter. To confirm the localization of the constructed 
mutants within the cell, the E2 protein and mutants were tagged with enhanced green 
fluorescent protein (eGFP). eGFP fluorescence can be detected under fluorescent light in 
the microscope and localization of the proteins can hence be determined. Introduction of 
either of the two additional NLS sites identified in low-risk HPV E2 into the HPV16 E2 
sequence resulted in a mainly nuclear localization of the protein. Activation of the human 
MMP-9 promoter as detected by reporter-gene assays was similar to that achieved by 
wild-type HPV16 E2. Mutation as well as deletion of the nuclear export sequence also 
resulted in a mainly nuclear localization of the E2 protein.In reporter-gene assays, 
however, the E2 mutant containing only a mutation within the NES resulted in a highly 
significant decrease in MMP-9 promoter activation as opposed to the NES deletion mutant 
which retained the activation capacity of wild-type E2. A study by … et al. has shown that 
a mutation of the amino acid at position 73 in the E2 sequence leads to a transactivation-
deficient protein, which has a reduced ability to induce papillomas in the context of the 
viral genome in-vivo (Jeckel et al., 2002). The I73A mutant has been shown to have a 
reduced capacity to activate the truncated 670bp human MMP-9 promoter in-vitro 
(Behren et al., 2005). Reporter-gene assays carried out with the described mutant and a 
full length human MMP-9 promoter resulted in a decrease in activation as previously 
described. In contrast to the NES mutant, this protein showed a nuclear and cytoplasmic 
distribution in the cell. As both, the amino acid exchanges in the NES mutant and the 
isoleucin at position 73 are located within close proximitiy to each other in the 
transactivation domain of the E2 protein, it may be that the decrease in promoter 
activation observed with the NES mutant is a result of a transactivation deficiency. This 
will have to be subject to further investigations. As the nuclearly localized proteins were 
able to activate the MMP-9 promoter, it was interesting to investigate whether the low-
risk HPV6b E2 protein, is able to induce an activation of the promoter as well. As this was 
shown to be the case, it can be hypothezised that the E2 protein induced MMP-9 
expression in HPV-infected cells via ERK and AP-1-mediated promoter activation by 
interaction with a nuclear mediator of unknown identity. Two methods were available in 
order to prove this theory. It is known that the nuclear import of the E2 protein occurs via 
the exportin-1 receptor (CRM1) which can be inhibited by addition of actinomycin D. 
However, the import of MAP-kinases into the nucleus occurrs by a similar mechanism and 
hence inhibition of nuclear import would have led to unclear results in the reporter-gene 
assays. Therefore, an NLS deletion mutant was constructed which was to be localized 
within only the cytoplasm of the cells. Immunofluorescence of the created mutant 
confirmed a mainly cytoplasmic localization of the protein. Reporter-gene assays showed 
a significant decrease in the activation potential of the cytoplasmic E2 mutant. As the 
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mutation introduced is not located within the transactivation domain of the E2 protein, 
but within the DNA-binding domain, this decrease in activation cannot be accounted for 
by a loss in transactivation efficiency. Furthermore, as activation of the promoter cannot 
be due to direct binding of the E2 protein to the MMP-9 promoter, as no consensus 
sequence was detected, this decrease in activation must be a result of the change in E2 
localization. Interestingly, when investigated by immunofluorescence, a previously 
described DNA-binding deficient E2 mutant (E2 306/307), which has also been shown to 
have a lowered promoter activation potential, was also found to by of mainly cytoplasmic 
localization.  
 
In this study, we have been able to show that binding of the transcription-factor AP-1 to 
the MMP-9 promoter is important for the activation of the promoter by papillomavirus E2. 
Futhermore, by using ERK1 and -2 dominant negative mutants it was determined that 
both ERK proteins effect the activation of the promoter. Using chemical inhibitors, we 
ruled out that the JNK and the p38 pathway contribute largely to the activation of the 
MMP-9 promoter by papillomavirus E2. However, MEK1, an activator of ERK was shown to 
be involved in the activation of ERK and thus of the MMP-9 promoter. 
Taking all of the results obtained within the course of this study together, part of the 
mechanism can be proposed by which the activation of the MMP-9 promoter is induced by 
the papillomavirus E2 protein. It can be concluded that the E2 protein binds intracellularly 
to either another protein by protein-protein interaction or to the promoter of a yet 
unknown gene whose expression is thereby induced. In either way, signalling occurrs 
within the cytoplasm or via a receptor and ultimately leads to the phosphorylation of ERK, 
a step which involves activation of MEK1. ERK then leads to the activation of an AP-1 
complex in which c-Jun plays a major role. The resulting AP-1 complex binds to 
promoters of tumor-progression promoting genes such as MMP-9 and uPA and initiates 
gene expression (Figure 54).  
As the proposed mechanism is still incomplete and contains a lot of unknown factors, it 
will have to be subject to further investigation.  
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Figure 54: Schematic illustration of proposed mechanisn of E2-mediated MMP-9 promoter 
activation. 
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 -XI- 
Attachment 1: 
Sequence of the rabbit MMP-9 promoter 
 
TCCAACCCAT TCGCCTATAC CTGGTCCTCT CAGTTCCCTG TAAACAGTAA -1804 
TACAAATCCA AGGCTTCAGA ACCAGGCAGC CCGAGTTCTG TGTGCCAACC -1754 
TGCTGTGTGA CCTCTGGCAA GTTCCTTAGC TGTGCTGAGC CTGTTCTTCC -1704 
TCTGAGAAAC CAACCTCATA GACAGTAAGG ATGAGACGAG AGGCTCACGG -1654 
AGAGCTTATC ACAGTGTTGG ACCATACAGT AAGTCTCAAA ACACTGCCTT -1604 
CTGATGGCTC AGAAGGGAGT GACTTTGCCC AAGGTTACAG AACTGGAACT -1554 
GGCAGAGCTG GGACGGAGAT CCAGGACTGT GTGACCCCAG AGCAGGTGCT -1504 
CACTAATTAG TGGAGCTTAG AGCTTCCGCT TTCCTATCCA GGACGTCAGC -1454 
TGTCTCCATC GCCATGGAGT CATTTATCAG AAAAGCACAG CTGGTGCCCG -1404 
GCACATAGTA GGCTCTTTAA ACATAGCGTG TGTTCTTTCC AGGCAAGGCA -1354 
GCCGGCCGTG AGCCTGTCCT ACGCTGGCTG CCCGGGAGGC AGGGGGAAAG -1304 
GAAGCTGCTG GTTGTTGGGA GAAGCGGTGA GGACTGGGGC GGAAGCTTTT -1254 
GTGAGCAGGG CTGGGGAACG GGGAGGCCAG CTGAGGAATC CAGGACCCAG -1204 
GAAGGGGAAG GCGTGGACTC TAGTCACACA GCAGCTCAGA GCCCAAGCCT -1154 
TCCGCCTCCT GGTTTTAGGT TGGATTCATG ATCTTGGCCT TGACAGTGAA -1104 
AAGCAGTCAC TGATGTTTTA ACAACAGCAC CCACCATGCT AAGCATTCTG -1054 
TATGTTTATT TTCATATCAA TTTAGGGACA AAGGGATGAT TTAAAAAAAT -1004 
CTATTTATTC AAAACCAGGG GGCGGAGAGG GGGAGAGAAT GCCAGCTACC -954 
TTGTACTAGT AGTTCACTCT GCAAATACTT GCAACAGCCA GGTGCCGGGC -904 
CAAGAGCTTA TAATTCCATC TGCGTCTCCC ACGCAGGTGG CAGGGACTCA -854 
AGTACTTGAG CCGTCACCTG CTGCCTCCCA GGGTGACACC AGCAGGAAGC -804 
TGGGTGAGAA GTAGAGCTGG GGCTGGAACC CAGGCCCTCC AGTGCAGGAT -754 
GCAAGCATCC TAAGCAGTGT TTTAGTCACA GCATCCAACA CCTGCCGGGG -704 
GGGGGGGGTG CTATTTTTTG ACAGCCGAGC AAAGAAGTCC CCAGTGGTGA -654 
GGCCGTGTGC CCGAGGCCCT CAGGGAGCAC CGTGAGGCTG TCTGCTGAGC -604 
TCTCCCCATC ACTGCCCTGA AGATTCAGCC TGTCGGAGAC AGGGGGTTAC -554 
CCCGGTGGAA TTCCCCAAAT CCTGCCTCAG AGAGCCCACT CCTTCCGCCC -504 
AGCTGGAGCC GGGAGGAGGA AGCTGAGTCA GAGGAGGGCT TTCCAGGAGG -454 
GAGGACGTAG CCTGCGGGGA GAGCCTCAGG AGGGGGTGTC ACAGAGTCAA -404 
GGGTGGGCCT GGGGTGGCAC TCAGGAAGGG GGTCCCAGGG CGTCCAACAT -354 
CCTTTCGCTG AGCTGACCAC TTGGGACCTC CTACCCCGTC CCTCTCCCTC -304 
CTGTTCCCAC AAACGCTGCA GTTTGCAAAA CCCAACCGCT CCCCTGAGGG -254 
CCTGTGGTTT CCTGTGGGTC TGGGGTCCTG CCTGACTCGG CAGCGGGGAC -204 
TGCAGGCGGG TGGGGGGAGA GGCGGGGGGA GAGGAGGTGG TGAAAATCTG -154 
TTCTTTGCCT TCTCATGCTG GGGCTGCCCC CTTCCCCCCT GCACCGGCCC -104 
TGAGTCAGGC ACTTGCCTGC AGGAAGAGGG GCGGGGTCAC GACTCAGGAG -54 
TGCCTCTTTA AAGCCCCCGC TGCCGTCGTG CGCCAGACGC TGCTCCCCTC -4    
ACCATGAGCC CCAGACAGCC CC                             +18  
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Attachment 2: 
Clustal W alignment of the rabbit and human MMP-9 promoters 
 
NZW             ----------------TCCAACCCATTCGC--CTATACCTGG-TCCTCTCAGTTCCCTGT -1812 
hum             CTGCCCCTGTCACCGCATCCACCTACCCACTTCTATACCTGGGTCATCACAGTTCCCTGT -2222 
                                  * *** *  * *  ********** ** ** *********** 
 
NZW             AAACAGTAATACAAATCCAAGGCTTCAGAACCAGGCAGCCCG-------------AGTTC -1765 
hum             AAATGGTAATAAAGATGAAAAGCTTCAGAGCCAGGCAGTTCTGGGCTTGAACACTAGTTC -2162 
                ***  ****** * **  ** ******** ********  *              ***** 
 
NZW             TGTGTGCCAACCTGCTGTGTGACCTCTGGCAAGTTCCTTAGCTGTGCTGAGCCTG---TT -1708 
hum             TGTGGATTAACTCGCTCTGTGATCACAGGCAAATTCCTTAACTCT-CTGAGCCTTAGTTT -2103 
                ****    ***  *** ***** * * ***** ******* ** * ********    ** 
 
NZW             CTTCCTCTGAGAA-------------------ACCAACCTCATAGACAGTAAGGATGAGA -1667 
hum             CCCCCTCTGAAAACAGGAGGGATACTCATTAAACTTACCTTACAGGTGGTGAGGATGAAA -2043 
                *  ******* **                   **  **** * **   ** ******* * 
 
NZW             CGAGAGGCTCACGGAGAGCTTATCACAGTGTTGGACCATACAGTAAGTCTCAAAA----C -1611 
hum             CGAGAGGCTTATAGAGAACTTATTACGGTGCTTGAC---ACAGTAAATCTCAAAAAATGC -1986 
                ********* *  **** ***** ** *** * ***   ******* ********    * 
 
NZW             ACTGCC-TTCTGATGGCTCAGAAG-GGAGTGACTTTGCCCAAGGTTACAGAACTGGAAC- -1554 
hum             ATTATTATTATTATGGTTCAGAGGTAAAGTGACTT-GCCCAAGGTCACATAGCTGGAAAA -1927 
                * *    ** * **** ***** *   ******** ********* *** * ******   
 
NZW             TGGCAGAGCTGGGACGGAGATCCAGGACTGTGTGACCCCAGAGCAGGTGCTCACTAATTA -1494 
hum             TGGCAGAGCCGGGATGGAAATCCAGGACTTCGTGACTGCAAAGCAGATGTTCATTGGTTA -1867 
                ********* **** *** **********  *****  ** ***** ** *** *  *** 
 
NZW             GTGGAGCTTAGAGCTTCCGCTTTCCTATCCAGGACGTCAGCTGTCTCCATCGCCATGGAG -1434 
hum             GTGAACTTTAGAACTTCAACTTTTCTGTAAAGGAAGTTAATTATCTCCATC-TCACAGTC -1808 
                *** *  ***** ****  **** ** *  **** ** *  * ********  **  *   
 
NZW             TCATTTATCAGAAAAGCACAGCTGGTGCCCGGCACATAGTAGGCTCTTTAAACATAGCGT -1374 
hum             TCATTTATTAGATAAGCATATAAAATGCCTGGCACATAGTAGGCCCTTTAAATACAGCTT -1748 
                ******** *** ***** *     **** ************** ******* * *** * 
 
NZW             GTGTTCTTTCCAGGCAAGGCAGCCGGCCGTGAGCCTGTCCT------ACGCTGGCTGCCC -1320 
hum             ATTGGGCCGGGCGCCATGGCTCATGCCCGTAATCCTAGCACTTTGGGAGGCCAGGTGGGC -1688 
                 *          * ** ***    * **** * ***  *        * **  * **  * 
 
NZW             GG-------GAGGCAGGGG---GAAAGGAAGCTGCTGGTTGTTGGGAGANGCGGTGAGGA -1270 
hum             AGATCACTTGAGTCAGAAGTTCGAAACCAGCCTGGTCAACGTAGTGAAACCCCATCTCTA -1628 
                 *       *** ***  *   ****  *  *** *    ** * ** *  *  *    * 
 
NZW             CTGGGG---CGGAAGCTTTTGTGAGCAGGGCTGGGGAACG-------------------G -1232 
hum             CTAAAAATACAAAAAATTTAGCCAGGCGTGGTGGCGCACGCCTATAATACCAGCTACTCG -1568 
                **       *  **  *** *  **  * * *** * ***                   * 
 
NZW             GGAGGCCA--GCTGAGGAAT--CCAGGACCCAGGAAGGGGAAGGCG---TGGACTCTAGT -1179 
hum             GGAGGCTGAGGCAGGAGAATTGCTTGAACCCGGGAGGCAGATGTTGCAGTGAGCCGAGAT -1508 
                ******    ** *  ****  *  * **** *** *  ** *  *   **  *     * 
 
NZW             CACACAGCAGCTCAG-AGCCCAAGC------------CTTCCGCCTCCTGGTTTTAGGTT -1132 
hum             CACGCCACTGCACTCCAGCCTGGGTGACAGAGTGATACTACACCCCCCAAAAATAAAATA -1448 
                *** *  * ** *   ****   *             ** *  ** **     * *  *  
 
NZW             GGATTCATGATCTTGGCCTTGACAGTGAAAAGCAG-----TCACTGAT---GTTTTAACA -1080 
hum             AAATAAATAAATACAACTTTTTGAGTTGTTAGCAGGTTTTTCCCAAATAGGGCTTTGAAG -1388 
                  **  ** *      * **   ***    *****     ** *  **   * *** *   
 
NZW             ACAGCA---------CCCACC--ATGCT---------------AAGCATTCTGTATGTTT -1046 
hum             AAGGTGAATATAGACCCTGCCCGATGCCGGCTGGCTAGGAAGAAAGGAGTGAGGGAGGCT -1328 
                *  *           **  **  ****                *** * *  *   *  * 
 
  ATTACHMENTS 
 
 
 -XIII- 
NZW             ATTTTCATATCAATTTAGGGACAAAGGGATGATTTAAA----AAAAT-----CTATTTAT -995 
hum             GCTGGTGTGGGAGGCTTGGGAGGGAGGCTTGGCATAAGTGTGATAATTGGGGCTGGAGAT -1268 
                  *    *   *   * ****   ***  **   ***     * ***     **    ** 
 
NZW             TCAAAACCAGGGGGCGGAGAGGGGGA---GAGAATGCC------AGCTACCTTGTACTAG -944 
hum             TTGGCTGCATGGAGCAGGGCTGGAGAACTGAAAGGGCTCCTATAGATTATTTTCCCCCAT -1208 
                *      ** ** ** * *  ** **   ** *  **          **  **   * *  
 
NZW             ----TAGTTCACTCTGCAAATA------------CTTGCAACAG--------------CC -914 
hum             ATCCTGCCCCAATTTGCAGTTGAAGAATCCTAAGCTGACAAAGGGGAAGGCATTTACTCC -1148 
                    *    ** * ****  *             **  ***  *              ** 
 
NZW             AGGTGCCG----GGCCAAGAGCTTA--------------TAATTCCAT------------ -884 
hum             AGGTTACACTGCAGCTTAGAGCCCAATAACCTGGTTTGGTGATTCCAAGTTAGAATCATG -1088 
                ****  *      **  *****  *              * ******              
 
NZW             -------------------CTGCGTCTCCCACGCAGGTG-GCAGGGACTCAAGTA----- -849 
hum             GTCTTTTGGCAGGGTCTCGCTCTGTTGCCCAGGCTGGAGTGCAGTGACATAATCATGGCT -1028 
                                   **  **  **** ** ** * **** ***  **  *      
 
NZW             --CTTGAGCCGTCACCTGCT-----------------------------GCCTCCCAGGG -820 
hum             CACTGTATCCTTGACCTTCTTTCTGGGCTCAAGCAATCCTCCCACCTCGGCCTCCCAAAG -968 
                  **  * ** * **** **                             ********  * 
 
NZW             TGACACCA--GCAGGAA-----------GCTGGG---TGAGAAGTAGAGCTGGGGCTGG- -777 
hum             TGCTAAGATTACAGGAATGAGCCACCATACCTGGCCCTGAATCTTGGGTCTTGGCCTTAG -908 
                **  *  *   ******            *  **   ***    * *  ** ** **    
 
NZW             ------AACCCAG-----GCCCTCCAGTGCAGGAT-GCAA------GCATCCTAAGCAGT -735 
hum             TAATTAAAACCAATCACCACCATCCGTTGCGGACTTACAACCTACAGTGTTCTAAACATT -848 
                      ** ***       ** ***  *** *  *  ***      *  * **** ** * 
 
NZW             GTTTTAGTC--ACAGCATCCAACACCTGC-------CGGGGGGGGGGGGTGC-------- -692 
hum             TTATATGTTTGATCTCATTTAATCCTCACATCAATTTAGGGACAAAGAGCCCCCCACCCC -788 
                 * *  **   *   ***  **  *   *         ***     * *  *         
 
NZW             -----TATTTTTTGACAGCCGAGCAAAGAAGTCCCCAGTGGTGAGGCCGTGTGCCCGAGG -637 
hum             CCGTTTTTTTTTTTACAGCTGAGGAAACAC-TTCAAAGTGGTAAGAC-ATTTGCCCGAGG -730 
                     * ****** ***** *** *** *  * *  ****** ** *  * ********* 
 
NZW             CCCTCAGGGAGCACCGTGAGGC--TGTCTGCTGAGCTCT---------------CCCCAT -594 
hum             TCCTGAAGGAAGAGAGTAAAGCCATGTCTGCTGTTTTCTAGAGGCTGCTACTGTCCCCTT -670 
                 *** * ***  *  ** * **  *********   ***               **** * 
 
NZW             CACTGCCCTGAAGATTCAGCCTGTCGGAGACAGGGGGTTACCCCGGTGGAATTCCCCAAA -534 
hum             TACTGCCCTGAAGATTCAGCCTGCGGAAGACAGGGGGTTGCCCCAGTGGAATTCCCCAG- -611 
                 **********************  * ************ **** *************   
 
NZW             TCCTGCCTCAGAGAGCCCACTCCTTCCGCCC--AGCTGGAGCCGGGAGGAGGAAGCTGAG -476 
hum             CCTTGCCTAGCAGAGCCCATTCCTTCCGCCCCCAGATGAAGCAGGGAG-AGGAAGCTGAG -552 
                 * *****   ******** ***********  ** ** *** ***** *********** 
 
NZW             TCAGAGGAGGGCTTTCCAGGAGGGA------GGACGTANCCTN-----CGGGGAGAGCCT -427 
hum             TCA-AAGAAGGCTGTCAGGGAGGGAAAAAGAGGACAGAGCCTGGAGTGTGGGGAGGGGTT -493 
                *** * ** **** **  *******      ****  * ***       ****** *  * 
 
NZW             CAGG------------------AGGGGGTGTCACAGA--GTCAAGGGTGGGCCTGGGGTG -387 
hum             TGGGGAGGATATCTGACCTGGGAGGGGGTGTTGCAAAAGGCCAAGGATGGGCCAGGGGGA -433 
                  **                  *********  ** *  * ***** ****** ****   
 
NZW             GCACTCA----GGAAGGGGGTCCCAGGGCGTCCAACATC-CTTTNGNTGAGCTGACCACT -332 
hum             TCATTAGTTTCAGAAAGAAGTCTCAGGGAGTCTTCCATCACTTTCCCTTGGCTGACCACT -373 
                 ** *       *** *  *** ***** ***   **** ****   *  ********** 
 
NZW             TGGGAC-------------------------CTCCTACCCCGTCCCTCTCCCTCCT---- -301 
hum             GGAGGCTTTCAGACCAAGGGATGGGGGATCCCTCCAGCTTCATCCCCCTCCCTCCCTTTC -313 
                 * * *                         ****  *  * **** ********      
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 -XIV- 
NZW             -----GTTCCCACAAACGCTGCAGTTTGCAAAACCCAACCGCTCCCCTGAGGGCCTGTGG -246 
hum             ATACAGTTCCCACAAGCTCTGCAGTTTGCAAAACCCTACCCCTCCCCTGAGGGCCTGCGG -253 
                     ********** * ****************** *** **************** ** 
 
NZW             TTTCCTGTGGGTCTGGGGTCCTGCCTGACTCGGCAGCGGGGACTGCAGGCGGGTGGGGGG -186 
hum             TTTCCTGCGGGTCTGGGGTCTTGCCTGACTTGGCAGTGGAGACTGCGGGCAGTGGAGAGA -193 
                ******* ************ ********* ***** ** ****** *** *  * * *  
 
NZW             AGAGGCGGGGGGAGAGGAGGTGGTGAAAATCTGTTCTTT---------GCCTTCTCATGC -135 
hum             GGAGGAGGTGGTGTAAGCCCTTTCTCATGCTGGTGCTGCCACACACACACACACACACAC -133 
                 **** ** **   * *   *     *     ** **            *   * **  * 
 
NZW             TGGGGCTGCCCCCTTCCCCCCTGCACC---GGCCCTGAGTCAGGCACTTGCCTGCAGGAA -78 
hum             ACACACACACACACACACACACACACCCTGACCCCTGAGTCAG-CACTTGCCTGTCA-AG -75 
                     *   * *   * * *   ****     *********** **********    *  
 
NZW             GAGGGGCGGGGTCACGACTCAGGAGTGCCTCTTTAAAGCCCCCGCTGCCGTCG-TGC-GC -20 
hum             GAGGGGTGGGGTCAC-----AGGAGCGCCTCCTTAAAGCCCCCACAACAGCAGCTGCAGT -20 
                ****** ********     ***** ***** *********** *  * *  * *** *  
 
NZW             CAGACGCTGCTCCCCTCACCATGAGCCCCAGACAGCCCC +19 
hum             CAGACACCTCTGCCCTCACCATGAGCCTCTGGCAGCCCC +19 
                ***** *  ** *************** * * *******        
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  ATTACHMENTS 
 
 
 -XV- 
Attachment 3: 
Alignment of the amino acid sequences of the HPV16E2 mutants used in this study 
 
 
HPV16E2         METLCQRLNVCQDKILTHYENDSTDLRDHIDYWKHMRLECAIYYKAREMGFKHINHQVVP 60 
E2NESmt         METLCQRLNVCQDKILTHYENDSTDLRDHIDYWKHMRLECAIYYKAREMGFKHINHQVVP 60 
E2NESdel        METLCQRLNVCQDKILTHYENDSTDLRDHIDYWKHMRLECAIYYKAREMGFKHINHQVVP 60 
E2I73A          METLCQRLNVCQDKILTHYENDSTDLRDHIDYWKHMRLECAIYYKAREMGFKHINHQVVP 60 
E2NLS1          METLCQRLNVCQDKILTHYENDSTDLRDHIDYWKHMRLECAIYYKAREMGFKHINHQVVP 60 
E2NLS2          METLCQRLNVCQDKILTHYENDSTDLRDHIDYWKHMRLECAIYYKAREMGFKHINHQVVP 60 
E2306/307       METLCQRLNVCQDKILTHYENDSTDLRDHIDYWKHMRLECAIYYKAREMGFKHINHQVVP 60 
E2NLSdel        METLCQRLNVCQDKILTHYENDSTDLRDHIDYWKHMRLECAIYYKAREMGFKHINHQVVP 60 
    
 
HPV16E2         TLAVSKNKALQAIELQLTLETIYNSQYSNEKWTLQDVSLEVLTAPTGCIKKHGYTVEVQF 120 
E2NESmt         TLAVSKNKALQAIELQPTLETIYNSQYSNEKWTLQDVSLEVLTAPTGCIKKHGYTVEVQF 120 
E2NESdel        TLAVSKNKALQA-------ETIYNSQYSNEKWTLQDVSLEVLTAPTGCIKKHGYTVEVQF 113 
E2I73A          TLAVSKNKALQAAELQLTLETIYNSQYSNEKWTLQDVSLEVLTAPTGCIKKHGYTVEVQF 120 
E2NLS1          TLAVSKNKALQAIELQLTLETIYNSQYSNEKWTLQDVSLEVLTAPKRCIKKHGYTVEVQF 120 
E2NLS2          TLAVSKNKALQAIELQLTLETIYNSQYSNEKWTLQDVSLEVLTAPTGCIKKHGYTVEVQF 120 
E2306/307       TLAVSKNKALQAIELQLTLETIYNSQYSNEKWTLQDVSLEVLTAPTGCIKKHGYTVEVQF 120 
E2NLSdel        TLAVSKNKALQAIELQLTLETIYNSQYSNEKWTLQDVSLEVLTAPTGCIKKHGYTVEVQF 120 
             
     
HPV16E2         DGDICNTMHYTNWTHIYICEEASVTVVEGQVDYYGLYYVHEGIRTYFVQFKDDAEKYSKN 180 
E2NESmt         DGDICNTMHYTNWTHIYICEEASVTVVEGQVDYYGLYYVHEGIRTYFVQFKDDAEKYSKN 180 
E2NESdel        DGDICNTMHYTNWTHIYICEEASVTVVEGQVDYYGLYYVHEGIRTYFVQFKDDAEKYSKN 173 
E2I73A          DGDICNTMHYTNWTHIYICEEASVTVVEGQVDYYGLYYVHEGIRTYFVQFKDDAEKYSKN 180 
E2NLS1          DGDICNTMHYTNWTHIYICEEASVTVVEGQVDYYGLYYVHEGIRTYFVQFKDDAEKYSKN 180 
E2NLS2          DGDICNTMHYTNWTHIYICEEASVTVVEGQVDYYGLYYVHEGIRTYFVQFKDDAEKYSKN 180 
E2306/307       DGDICNTMHYTNWTHIYICEEASVTVVEGQVDYYGLYYVHEGIRTYFVQFKDDAEKYSKN 180 
E2NLSdel        DGDICNTMHYTNWTHIYICEEASVTVVEGQVDYYGLYYVHEGIRTYFVQFKDDAEKYSKN 180 
                 
 
HPV16E2         KVWEVHAGGQVILCPTSVFSSNEVSSPEIIRQHLANHPAATHTKAVALGTEETQTTIQRP 240 
E2NESmt         KVWEVHAGGQVILCPTSVFSSNEVSSPEIIRQHLANHPAATHTKAVALGTEETQTTIQRP 240 
E2NESdel        KVWEVHAGGQVILCPTSVFSSNEVSSPEIIRQHLANHPAATHTKAVALGTEETQTTIQRP 233 
E2I73A          KVWEVHAGGQVILCPTSVFSSNEVSSPEIIRQHLANHPAATHTKAVALGTEETQTTIQRP 240 
E2NLS1          KVWEVHAGGQVILCPTSVFSSNEVSSPEIIRQHLANHPAATHTKAVALGTEETQTTIQRP 240 
E2NLS2          KVWEVHAGGQVILCPTSVFSSNEVSSPEIIRQHLANHPAATHTKAVALGTEETQTTIQRK 240 
E2306/307       KVWEVHAGGQVILCPTSVFSSNEVSSPEIIRQHLANHPAATHTKAVALGTEETQTTIQRP 240 
E2NLSdel        KVWEVHAGGQVILCPTSVFSSNEVSSPEIIRQHLANHPAATHTKAVALGTEETQTTIQRP 240 
                 
 
HPV16E2         RSEPDTGNPCHTTKLLHRDSVDSAPILTAFNSSHKGRINCNSNTTPIVHLKGDANTLKCL 300 
E2NESmt         RSEPDTGNPCHTTKLLHRDSVDSAPILTAFNSSHKGRINCNSNTTPIVHLKGDANTLKCL 300 
E2NESdel        RSEPDTGNPCHTTKLLHRDSVDSAPILTAFNSSHKGRINCNSNTTPIVHLKGDANTLKCL 293 
E2I73A          RSEPDTGNPCHTTKLLHRDSVDSAPILTAFNSSHKGRINCNSNTTPIVHLKGDANTLKCL 300 
E2NLS1          RSEPDTGNPCHTTKLLHRDSVDSAPILTAFNSSHKGRINCNSNTTPIVHLKGDANTLKCL 300 
E2NLS2          RSRPDTGNPCHTTKLLHRDSVDSAPILTAFNSSHKGRINCNSNTTPIVHLKGDANTLKCL 300 
E2306/307       RSEPDTGNPCHTTKLLHRDSVDSAPILTAFNSSHKGRINCNSNTTPIVHLKGDANTLKCL 300 
E2NLSdel        RSEPDTGNPCHTTKLLHRDSVDSAPILTAFNSSHKGRINCNSNTTPIVHLKGDANTLKCL 300 
                 
 
HPV16E2         RYRFKKHCTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWQRDQFLSQVKIPKTITVSTG 360 
E2NESmt         RYRFKKHCTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWQRDQFLSQVKIPKTITVSTG 360 
E2NESdel        RYRFKKHCTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWQRDQFLSQVKIPKTITVSTG 353 
E2I73A          RYRFKKHCTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWQRDQFLSQVKIPKTITVSTG 360 
E2NLS1          RYRFKKHCTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWQRDQFLSQVKIPKTITVSTG 360 
E2NLS2          RYRFKKHCTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWQRDQFLSQVKIPKTITVSTG 360 
E2306/307       RYRFAAHCTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWQRDQFLSQVKIPKTITVSTG 360 
E2NLSdel        GYGFTKHCTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWQRDQFLSQVKIPKTITVSTG 360 
                  
 
 
 
 
  ATTACHMENTS 
 
 
 -XVI- 
HPV16E2         FMSI 364 
E2NESmt         FMSI 364 
E2NESdel        FMSI 357 
E2I73A          FMSI 364 
E2NLS1          FMSI 364 
E2NLS2          FMSI 364 
E2306/307       FMSI 364 
E2NLSdel        FMSI 364                 
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